

Approved



**Ethiopia**  
**Country Operational Plan**  
**FY 2016**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		396,382		396,382	174,218	570,600
USAID		68,941,711		68,941,711	25,412,329	94,354,040
DOD		194,506		194,506	693,556	888,062
PC		0		0	610,343	610,343
HHS/CDC	2,787,500	79,851,832		82,639,332	8,252,623	90,891,955
HHS/HRSA		1,035,000		1,035,000	0	1,035,000
State/AF		350,000		350,000	5,000,000	5,350,000
State/PRM		2,000,000		2,000,000	0	2,000,000
<b>Total</b>	<b>2,787,500</b>	<b>152,769,431</b>	<b>0</b>	<b>155,556,931</b>	<b>40,143,069</b>	<b>195,700,000</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	State/AF	State/PRM	USAID		
CIRC	512	11,930	127,247			122,400	40,887	0	302,976
HBHC	717		6,496,138			208,911	10,887,664	0	17,593,430
HKID	2,047					0	11,361,731	0	11,363,778
HLAB	0	0	2,160,964				850,993	0	3,011,957
HMBL	0	11,930	2,000,021					0	2,011,951
HMIN	512	4,864	8,911			0	8,075	0	22,362
HTXD	0							0	0
HTXS	410		39,224,259			439,846	12,773,521	0	52,438,036
HVAB	10,999						0	0	10,999

Approved



HVCT	6,522	581	3,005,675			309,750	2,272,228	0	<b>5,594,756</b>
HVMS	298,157	113,427	7,260,484				2,207,908	0	<b>9,879,976</b>
HVOP	9,081	48,531	2,908,600			605,114	9,693,484	0	<b>13,264,810</b>
HVSI	38,907	3,243	5,097,781			50,000	3,040,925	0	<b>8,230,856</b>
HVTB	5,499		2,967,220			44,457	2,468,034	0	<b>5,485,210</b>
IDUP	0							0	<b>0</b>
MTCT	6,522		3,126,646			197,115	2,432,192	0	<b>5,762,475</b>
OHSS	5,499		3,126,426	1,035,000	350,000		9,701,536	0	<b>14,218,461</b>
PDCS	5,499		993,929			4,344	444,226	0	<b>1,447,998</b>
PDTX	5,499		4,135,031			18,063	758,307	0	<b>4,916,900</b>
	<b>396,382</b>	<b>194,506</b>	<b>82,639,332</b>	<b>1,035,000</b>	<b>350,000</b>	<b>2,000,000</b>	<b>68,941,711</b>	<b>0</b>	<b>155,556,931</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	17,389,547	0
HKID	11,275,901	0
HVTB	5,313,265	0
PDCS	1,336,804	0
<b>Total Technical Area Planned Funding:</b>	<b>35,315,517</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	2,706,756	0
HVSI	7,633,979	0
OHSS	14,076,190	0
<b>Total Technical Area Planned Funding:</b>	<b>24,416,925</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	272,210	0
HMBL	1,959,218	0
HMIN	0	
HVCT	5,433,209	0
HVOP	12,996,803	0
MTCT	5,439,159	0
<b>Total Technical Area Planned Funding:</b>	<b>26,100,599</b>	<b>0</b>

Approved



**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>	<b>On Hold Amount</b>
HTXS	51,701,551	0
PDTX	4,747,490	0
<b>Total Technical Area Planned Funding:</b>	<b>56,449,041</b>	<b>0</b>



### Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,334,397
	Number of new ANC and L&D clients	1,428,345
	By: Known positives at entry	10,241
	By: Number of new positives identified	6,376
	Sum of Positives Status disaggregates	16,617
	Required only for DREAMS Countries - By Number of new positives: <15	
	Required only for DREAMS Countries - By Number of new positives: 15-19	
	Required only for DREAMS Countries - By Number of new positives: 20-24	
	Required only for DREAMS Countries - By Number of known positives: <15	
	Required only for DREAMS Countries - By Number of known	



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	
	Required only for DREAMS Countries - Denominator: <15	
	Required only for DREAMS Countries - Denominator: <15-19	
	Required only for DREAMS Countries - Denominator: 20-24	
	Required only for DREAMS Countries - Denominator: 25-49	
	Required only for DREAMS Countries - Denominator: 50+	
	Required only for DREAMS Countries - By Number of known positives: 25-49	
	Required only for DREAMS Countries - By Number of known positives: 50+	
	Required only for DREAMS Countries - By Number of new positives: 25-49	
	Required only for DREAMS Countries - By Number of new positives: 50+	
	By Age (DREAMS SNUs ONLY): <15	0
	By Age (DREAMS SNUs ONLY): 15-19	
	By Age (DREAMS SNUs ONLY): 20-24	
	By Age (DREAMS SNUs ONLY): 25-49	



	By Age (DREAMS SNU's ONLY): 50+	
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	74,861
	Number of new ANC and L&D clients	78,328
	By: Known positives at entry	1,062
	By: Number of new positives identified	577
	Sum of Positives Status disaggregates	1,639
	Required only for DREAMS countries - By known positives: <15	
	Required only for DREAMS countries - By known positives: 15-19	
	Required only for DREAMS countries - By known positives: 20-24	
	Required only for DREAMS countries - By new positives: <15	
	Required only for DREAMS countries - By new positives: 15-19	
	Required only for DREAMS countries - By new positives: 20-24	
	Required only for DREAMS countries - Denominator: <15	





	Required only for DREAMS countries - Denominator: 15-19	
	Required only for DREAMS countries - Denominator: 20-24	
	Required only for DREAMS countries - Denominator: 25-49	
	Required only for DREAMS countries - Denominator: 50+	
	Required only for DREAMS countries - By known positives: 25-49	
	Required only for DREAMS countries - By known positives: 50+	
	Required only for DREAMS countries - By new positives: 25-49	
	Required only for DREAMS countries - By new positives: 50+	
	By Age (DREAMS SNUs ONLY): <15	0
	By Age (DREAMS SNUs ONLY): 15-19	
	By Age (DREAMS SNUs ONLY): 20-24	
	By Age (DREAMS SNUs ONLY): 25-49	
	By Age (DREAMS SNUs ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	



	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,334,397
	New on ART	6,173
	Already on ART at beginning of current pregnancy	9,325
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	74,861
	New on ART	549
	Already on ART at beginning of current pregnancy	1,065
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	17,184
	By Age: 0-60 days	179
	By Age: 2 months - 9 years	37
	By Age: 10-14	6,706
	By Age: 15-19	3,289
	By Age: 20-24	1,304
	By Age: 25-29	427
	By Age: 30-49	3,321
By Age: 50+	1,971	



	Sum of age disaggregates (Prior to FY15)	13,270
	Sum of age disaggregates (FY15-Current)	17,018
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	17,124
	By circumcision technique: Device-based VMMC	0
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have received antiretroviral preexposure	191



	Male 10-14	
	Male 15-19	
	Male 20-24	
	Male 25-49	
	Male 50+	
	Female 10-14	
	Female 15-19	
	Female 20-24	
	Female 25-49	
	Female 50+	
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	474,974
	Total number of people in the target population	1,762,890
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	



	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	209
	Aggregated Age/sex: 15+ Male	312,783
	Aggregated Age/sex: <15 Female	254
	Aggregated Age/sex: 15+ Female	58,411
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,080



	Total number of people in the target population	2,600
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Age/sex: <15 Male	0
	Aggregated Age/sex: 15+ Male	210
	Aggregated Age/sex: <15 Female	0
	Aggregated Age/sex: 15+ Female	1,870
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	92,794
	Total estimated number of key population in the catchment area	210,388
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of	



	key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards	92,789



	required)	
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type:	





	Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	209,140
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	



	By New Client Status: Rreturniong beneficiary within the current report period	
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,880
	Total estimated number of key population in the catchment area	2,350
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,880
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID)	



	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	2,350
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	



	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men and are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	



	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	444,492
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	



	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex:	



	Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	16,121
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	150,812
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	15,260
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	264,120
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	382
	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,309
	Test Result by Aggregated Age	227



	and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	8,773
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	70,000
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	111,612
	Service Delivery Point (Community): Other	44,662
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	6,915
	Service Delivery Point (Facility):	26,886





	Outpatient	
	Service Delivery Point (Facility): Pediatric	0
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	49,870
	Service Delivery Point (Facility): VCT	96,604
	Service Delivery Point (Facility): VMMC	2,842
	Service Delivery Point (Facility): PMTCT	29,131
	Service Delivery Point (Facility): TB Clinics	160
	Service Delivery Point (Facility): Index testing	0
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by	



	Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,895,768
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	



	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex:	



	Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	453,034
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,829,985
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	437,906
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,165,549
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	4,171
	Test Result by Aggregated Age	23,720



	and Sex: Positive 15+ Male	
	Test Result by Aggregated Age and Sex: Positive <15 Female	3,651
	Test Result by Aggregated Age and Sex: Positive 15+ Female	46,468
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	9,072
	Service Delivery Point (Community): Mobile testing	7,480
	Service Delivery Point (Community): Other	3,610
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility):	311,724



	Inpatient	
	Service Delivery Point (Facility): Outpatient	1,292,983
	Service Delivery Point (Facility): Pediatric	8,611
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	377,501
	Service Delivery Point (Facility): VCT	773,150
	Service Delivery Point (Facility): VMMC	0
	Service Delivery Point (Facility): PMTCT	953,589
	Service Delivery Point (Facility): TB Clinics	236,253
	Service Delivery Point (Facility): Index testing	5,697
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by	



	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.
Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		685



	Total number of registered new and relapsed TB cases, during the reporting period.	812
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	





	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	33
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	443
	Aggregated Age/Sex: Female <15	28



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	186
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of	



	registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	54,958
	Total number of registered new and relapsed TB cases, during the reporting period.	58,019
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with	



	documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,305
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	26,543
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,218
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	21,100
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total	



	number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	



	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	5,156
	Age/Sex: <10 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: <10 Female	1
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Sum of Age/Sex Disaggregates	1
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,179
	By type of service: Sexual Violence (Post-Rape Care)	3,002
	By PEP service provision (related to sexual violence services provided)	2,768
Age/Sex: 15-19 Female		
Age/Sex: 15-19 male		
GEND_GBV_TA	Number of people receiving post-GBV care	356





	Age/Sex: <10 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: <10 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Sum of Age/Sex Disaggregates	
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	145
	By type of service: Sexual Violence (Post-Rape Care)	211
	By PEP service provision (related to sexual violence services provided)	192
	Age/Sex: 15-19 Female	
	Age/Sex: 15-19 Male	
	OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS
Age/Sex: 10-14 Male		
Age/Sex: 15-17 Male		
By: Age/sex: Male 18-24		
By: Age/sex: Male 25+		
Age/Sex: 18+ Male		37,251
Age/Sex: 10-14 Female		
Age/Sex: 15-17 Female		
By: Age/sex: 18-24 Female		



	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	137,015
	Sum of Age/Sex disaggregates	174,266
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS	



	countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS	



	countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS	



	countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and	



	sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS	



	countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	157,416
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	145,378



	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	131
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	131
	Age/Sex: >1 (Numerator: The	





	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator:	



	<p>The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented</p>	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	105
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	26
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+	



	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed	n/a



	registered TB cases on ART during TB treatment	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	6,334
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	6,504
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented	





	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	399
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,324
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	275



	the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,491
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	<p>Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 20-24 (Denominator: The number of</p>	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB	



	cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	424,080
	Screened for TB by Age/Sex:<15 Male	18,543
	Screened for TB by Age/Sex: 15+ Male	146,723
	Screened for TB by Age/Sex:<15 Female	16,112
	Screened for TB by Age/Sex: 15+ Female	240,465
	Screen Result: Screened Positive for TB	42,282
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	34,854
	[Sub-Disagg of Specimen Sent]	10,107



	Diagnostic Test: Smear only	
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	14,319
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	10,889
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	9,500
	Screened for TB by Age/Sex: <15 Male	399
	Screened for TB by Age/Sex: 15+ Male	3,343
	Screened for TB by Age/Sex: <15 Female	367
	Screened for TB by Age/Sex: 15+ Female	5,391
	Screen Results: Screened Positive for TB	118
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	82
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	24
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	33



	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	25
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	12,349
	By infants who received their first virologic HIV test between 2 and 12 months of age	3,107
	Sum of Infant Age disaggregates	15,456
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	253
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive	127



	virological test result within 12 months of birth	
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	897
	By infants who received their first virologic HIV test between 2 and 12 months of age	209
	Sum of Infant Age disaggregates	1,106
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	17
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive	3





	virological test result within 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	479,742
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	22,250
	Aggregated Age/Sex: 15+ Male	165,914
	Aggregated Age/Sex: <15 Female	18,297
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	272,554
	Sum of Aggregated Age/Sex <15	40,547
	Sum of Aggregated Age/Sex 15+	438,468
	Sum of Aggregated Age/Sex disaggregates	479,015
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
Age/Sex: 25-49 Female		
Age/Sex: 50+ Female		



TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	20,661
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	440
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	8,911
	Aggregated Age/Sex: <15 Female	394
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	10,916
	Sum of Aggregated Age/Sex <15	834
	Sum of Aggregated Age/Sex 15+	19,827
	Sum of Aggregated Age/Sex disaggregates	20,661
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
Sum of Aggregated Age/Sex (<1 and 1-14) <15		



	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	75,470
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	1
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	1
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	5,216
Aggregated Grouping by Age/Sex: 1-14 Male		
Aggregated Grouping by Age/Sex: 15+ Male	23,414	
Aggregated Grouping by Age/Sex: <1 Female		



	Aggregated Grouping by Age/Sex: <15 Female	4,668
	Aggregated Grouping by Age/Sex: 15+ Female	42,045
	Sum of Aggregated Age/Sex disaggregates	75,343
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,842
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
Aggregated Grouping by Age: <1		



	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	117
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	2,670
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	88
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	2,952
	Sum of Aggregated Age/Sex disaggregates	5,827
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	246,509
	Number of adult and pediatric ART patients with a viral load result	301,953



	documented in the patient medical record and /or laboratory records in the past 12 months.	
	Numerator: Indication: Routine	198,223
	Numerator: Indication: Targeted	48,259
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication:	



	25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by	



	Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	242,543
	Denominator: Indication: Targeted	60,160
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by	





	Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex	



	by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	10,913
	Numerator Aggregated Age/Sex: 15+ Male	85,919
	Numerator Aggregated Age/Sex: <15 Female	9,589
	Numerator Aggregated Age/Sex: 15+ Female	140,030
	Denominator Aggregated Age/Sex: <15 Male	13,412
	Denominator Aggregated Age/Sex: 15+ Male	105,048
	Denominator Aggregated Age/Sex: <15 Female	11,708
	Denominator Aggregated Age/Sex: 15+ Female	171,045
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record	n/a



	and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	9,845
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	12,163
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	



	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	



Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
Numerator: Indication: Routine	9,286
Numerator: Indication: Targeted	559
Numerator: Preg/BF by Indication: Breastfeeding Routine	
Numerator: Preg/BF by Indication: Breastfeeding Targeted	
Numerator: Preg/BF by Indication: Pregnant Routine	
Numerator: Preg/BF by Indication: Pregnant Targeted	
Denominator: Indication: Routine	11,417
Denominator: Indication: Targeted	746
Denominator: Age/Sex by Indication: <1 Routine	
Denominator: Age/Sex by Indication: <1 Targeted	
Denominator: Age/Sex by Indication: 1-9 Routine	
Denominator: Age/Sex by Indication: 1-9 Targeted	
Denominator: Age/Sex by Indication: 10-14 Female Routine	
Denominator: Age/Sex by Indication: 10-14 Female Targeted	



	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	



	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	224
	Numerator Aggregated Age/Sex: 15+ Male	4,202
	Numerator Aggregated Age/Sex: <15 Female	199
	Numerator Aggregated Age/Sex: 15+ Female	5,180



	Denominator Aggregated Age/Sex: <15 Male	262
	Denominator Aggregated Age/Sex: 15+ Male	5,303
	Denominator Aggregated Age/Sex: <15 Female	234
	Denominator Aggregated Age/Sex: 15+ Female	6,484
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	35,833
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	40,520
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator:	





	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of	



	<p>adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,</p>	



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,071
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,098
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,707



	<p>Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	<p>20,630</p>
	<p>Aggregated Age/Sex: &lt;15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>2,291</p>
	<p>Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>12,560</p>
	<p>Aggregated Age/Sex: &lt;15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>1,934</p>
	<p>Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and</p>	<p>23,274</p>



	those lost to follow-up)	
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,675
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,021
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0



	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting)	0





	period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Age/Sex: 25-49 Male (Denominator: Total number of	0



	<p>adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>0</p>
	<p>Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>0</p>
	<p>Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>0</p>
	<p>Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,</p>	<p>0</p>



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	114
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	480
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	154
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	921
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated	148



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	567
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	191
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,112
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing:	1,103



	Number of laboratories that perform this testing	
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	1,103
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1,103
	CD4: Number of laboratories that perform this testing	237
	CD4: Number of laboratories that participate in this PT program	169
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	169
	Early infant diagnostics: Number of laboratories that perform this testing	19
	Early infant diagnostics: Number of laboratories that participate in this PT program	19
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	19
	HIV viral load: Number of laboratories that perform this testing	19
	HIV viral load: Number of laboratories that participate in this PT program	19
	HIV viral load: Number of laboratories that achieve acceptable successful passing	19



	criteria in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	1,038
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	235
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	235
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	93
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	22
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	22
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	10
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	10
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	10
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an	



	analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	CD4: Number of laboratories that participate in this PT program	
	CD4: Number of laboratories that perform this testing	
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that participate in this PT program	
	Early infant diagnostics: Number of laboratories that perform this testing	
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	259
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	259
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	259
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	HIV viral load: Number of laboratories that participate in this	





	PT program	
	HIV viral load: Number of laboratories that perform this testing	
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	180
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	180
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	180
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	
HRH_PRE	Number of new HCW who	13,563



	graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	
	By Graduates: Doctors	1,954
	By Graduates: Nurses	94
	By Graduates: Midwives	3,076
	By Graduates: Social service workers	2,000
	By Graduates: Laboratory professionals	28
	By Graduates: Other	6,411
	Sum of Graduates disaggreagtes	13,563



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7515	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	0
10515	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	96,320
10517	Hawassa University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	383,705
10548	Jimma University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	453,246
10557	Mekele University	University	U.S. Department of Health and Human Services/Centers	GHP-State	693,107



			for Disease Control and Prevention		
10559	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,050,158
10564	Population Council	NGO	U.S. Agency for International Development	GHP-State	150,000
10599	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	900,000
10601	Addis Ababa University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	504,892
10603	American Society of Clinical Pathology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10604	Association of Public Health	NGO	U.S. Department of Health and	GHP-State	143,859



	Laboratories		Human Services/Centers for Disease Control and Prevention		
10663	American Society for Microbiology	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
11033	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	350,000
11036	International Rescue Committee	NGO	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	0
11040	United Nations High Commissioner for Refugees	Multi-lateral Agency	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	2,000,000
12306	Organization for Social Services for AIDS (OSSA)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,874,346
12307	Pathfinder International	NGO	U.S. Department of Health and Human Services/Centers	GHP-State	0



			for Disease Control and Prevention		
12313	NETWORK OF NETWORKS OF ETHIOPIANS LIVING WITH HIV/AIDS (NEP+)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12314	Ethiopian Society of Obstetricians and Gynecologists	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12319	Federal Police, Ethiopia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,123,518
12321	Gondar University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	538,240
13053	Family Guidance Association of Ethiopia	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	0



			Control and Prevention		
13158	Federal Ministry of Health, Ethiopia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,425,068
13254	Tulane University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13456	Clinton Health Access Initiative	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13530	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13597	Mayo Clinic	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	0



			Control and Prevention		
13770	Harari Regional Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,132,139
13794	Oromia Health Bureau, Ethiopia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	8,908,463
13928	Addis Ababa HIV/AIDS Prevention and Control Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13929	Dire Dawa City Administration Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,280,554
13931	Federal HAPCO	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	182,880





			Prevention		
13932	Haramaya University	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	422,868
13933	Ethiopian Medical Association	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	187,306
13934	Addis Ababa Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,372,237
13948	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	135,000
14209	JHPIEGO	University	U.S. Agency for International Development	GHP-State	1,500,000
14210	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	971,706
14215	FHI 360	NGO	U.S. Agency for International Development	GHP-State	420,000



			International Development		
14217	World Food Program	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	1,595,000
14228	Population Services International	NGO	U.S. Agency for International Development	GHP-State	8,577,278
14230	World Learning	NGO	U.S. Agency for International Development	GHP-State	2,800,000
14232	Pact, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	185,901
14267	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	0
14309	World Health Organization	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	670,000
14351	National Network of Positive Women Ethiopia	NGO	U.S. Agency for International Development	GHP-State	205,000
16738	Ethiopian Public Health Association	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,154,393
16742	National Defense Forces of Ethiopia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers	GHP-State	2,151,178



			for Disease Control and Prevention		
16749	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	12,226,721
16750	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	837,370
16751	Ethiopian Public Health Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,473,180
16752	Amhara Regional Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,878,649
16779	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	85,503



			Control and Prevention		
16798	FHI 360	NGO	U.S. Department of Defense	GHP-State	31,736
16901	SNNPR	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,862,338
16912	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	3,800,000
16930	FHI 360	NGO	U.S. Agency for International Development	GHP-State	500,000
17000	Tigray Regional Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,524,745
17271	Ethiopian Society of Sociologists, Social Workers and Anthropologists	NGO	U.S. Agency for International Development	GHP-State	1,300,000
17635	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	2,000,000
17641	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	300,000



17746	Peace Corps Volunteers	Implementing Agency	U.S. Peace Corps	GHP-State	0
17824	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	4,988,294
17825	TBD	TBD	Redacted	Redacted	Redacted
17843	TBD	TBD	Redacted	Redacted	Redacted
17856	TBD	TBD	Redacted	Redacted	Redacted
17908	TBD	TBD	Redacted	Redacted	Redacted
18233	TBD	TBD	Redacted	Redacted	Redacted
18241	Tera Tech EM, INC	Implementing Agency	U.S. Agency for International Development	GHP-State	0
18242	TBD	TBD	Redacted	Redacted	Redacted
18265	TBD	TBD	Redacted	Redacted	Redacted
18337	TBD	TBD	Redacted	Redacted	Redacted
18338	TBD	TBD	Redacted	Redacted	Redacted
18339	TBD	TBD	Redacted	Redacted	Redacted
18340	TBD	TBD	Redacted	Redacted	Redacted
18341	TBD	TBD	Redacted	Redacted	Redacted
18375	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	16,086,433
18463	TBD	TBD	Redacted	Redacted	Redacted
18464	TBD	TBD	Redacted	Redacted	Redacted



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 7515</b>	<b>Mechanism Name: DoD Mech Ethiopia</b>
Funding Agency: DOD	Procurement Type: Contract
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 425,292</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 425,292</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 7515</b>			
<b>Mechanism Name: DoD Mech Ethiopia</b>			
<b>Prime Partner Name: U.S. Department of Defense (Defense)</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	3,200
VMMC_CIRC_DSD	By Age: 0-60 days	179
VMMC_CIRC_DSD	By Age: 2 months - 9 years	37
VMMC_CIRC_DSD	By Age: 10-14	142
VMMC_CIRC_DSD	By Age: 15-19	2,213
VMMC_CIRC_DSD	By Age: 20-24	577
VMMC_CIRC_DSD	By Age: 25-29	52
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	2,932
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	2,984
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	3,200
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,842
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,842
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,842
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,842
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	11
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	2,842

### Implementing Mechanism Details



<b>Mechanism ID: 10515</b>	<b>Mechanism Name: Capacity Building Assistance for Global HIV/AIDS Laboratory Guidelines and Standards Development and Enhancing Laboratory Quality Improvement Skills through Quality Systems Approach</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 96,320</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 96,320</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	96,320

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	10515		
<b>Mechanism Name:</b>	Capacity Building Assistance for Global HIV/AIDS Laboratory Guidelines and Standards Development and Enhancing Laboratory Quality Improvement Skills through Quality Systems Approach		
<b>Prime Partner Name:</b>	Clinical and Laboratory Standards Institute		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	96,320	0





## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 10517</b>	<b>Mechanism Name: TBD-G2G HIV/AIDS Antiretroviral Therapy Programme Implementation support through local universities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Hawassa University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 383,705</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 383,705</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	383,705

## Cross-Cutting Budget Attribution(s)

Human Resources for Health	81,872
Gender: GBV	6,500
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

### Budget Code Information

<b>Mechanism ID:</b>	10517		
<b>Mechanism Name:</b>	TBD-G2G HIV/AIDS Antiretroviral Therapy Programme Implementation		
<b>Prime Partner Name:</b>	support through local universities Hawassa University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	81,872	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	16,904	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	250,639	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	34,290	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,000



PP_PREV_DSD	Total number of people in the target population	1,000
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	334
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	666
GEND_GBV_DSD	Number of people receiving post-GBV care	50
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	20
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	30
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	27
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	5,014
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	287
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,834
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	297
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,596
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	584
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,430
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	5,014
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	612
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	49
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	192
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	51
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	320
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	612
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	2,600
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,250
TX_PVLS_DSD	Numerator: Indication: Routine	2,080



TX_PVLS_DSD	Numerator: Indication: Targeted	520
TX_PVLS_DSD	Denominator: Indication: Routine	2,600
TX_PVLS_DSD	Denominator: Indication: Targeted	650
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	149
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	951
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	154
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	1,346
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	186
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,189
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	192
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,683
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	386
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	421
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	122
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	222
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	133
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	242
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	272
HRH_PRE	By Graduates: Doctors	104
HRH_PRE	By Graduates: Nurses	39
HRH_PRE	By Graduates: Midwives	38
HRH_PRE	By Graduates: Social service workers	0
HRH_PRE	By Graduates: Laboratory professionals	28
HRH_PRE	By Graduates: Other	63
HRH_PRE	Sum of Graduates disaggreagtes	272

### Implementing Mechanism Details

<b>Mechanism ID: 10548</b>	<b>Mechanism Name: TBD-G2G HIV/AIDS Anti-Retroviral Therapy Programme Implementation Support through Local Universities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Jimma University	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 453,246</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 453,246</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	453,246

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	134,268
Gender: GBV	6,500
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	<b>10548</b>
<b>Mechanism Name:</b>	<b>TBD-G2G HIV/AIDS Anti-Retroviral Therapy Programme Implementation</b>
<b>Prime Partner Name:</b>	<b>Support through Local Universities</b>



Jimma University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	134,268	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	16,904	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	250,639	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	51,435	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,000
PP_PREV_DSD	Total number of people in the target population	1,100
PP_PREV_DSD	Aggregated Age/sex: <15 Male	10
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	340
PP_PREV_DSD	Aggregated Age/sex: <15 Female	20
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	630
GEND_GBV_DSD	Number of people receiving post-GBV care	50
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	20
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	30
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	27
TX_CURR_DSD	Number of adults and children receiving antiretroviral	4,856



	therapy (ART)	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	229
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,654
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	225
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,748
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	454
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,402
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,856
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,301
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	49
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	440
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	73
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	739
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,301
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	2,518
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,148
TX_PVLS_DSD	Numerator: Indication: Routine	2,014
TX_PVLS_DSD	Numerator: Indication: Targeted	504
TX_PVLS_DSD	Denominator: Indication: Routine	2,518
TX_PVLS_DSD	Denominator: Indication: Targeted	630
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	119
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	858
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	116
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	1,425
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	148
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,072
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	146





TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,782
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	227
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	247
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	71
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	131
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	78
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total	142



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	141
HRH_PRE	By Graduates: Doctors	141
HRH_PRE	Sum of Graduates disaggreagtes	141

**Implementing Mechanism Details**

<b>Mechanism ID: 10557</b>	<b>Mechanism Name: TBD-G2G HIV/AIDS Anti-Retroviral Therapy Program Implementation Support through Local Universities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mekele University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 693,107</b>	
<b>Applied Pipeline Amount: 87,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 780,107</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	693,107

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	134,268
Gender: GBV	10,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Food and Nutrition: Commodities	121,748

**Budget Code Information**

<b>Mechanism ID:</b>	10557		
<b>Mechanism Name:</b>	TBD-G2G HIV/AIDS Anti-Retroviral Therapy Program Implementation		
<b>Prime Partner Name:</b>	Support through Local Universities Mekele University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	134,268	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	15,411	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	86,925	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	430,786	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	PDTX	25,717	0
-----------	------	--------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,000
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,759
KP_PREV_DSD	Total estimated number of key population in the catchment area	4,134
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,759
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	4,134
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,150
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	32
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	158
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	32
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,928



HTC_TST_DSD	Sum of Aggregated Age/Sex <15	64
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,086
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	3,150
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	2
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	10
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	2
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	122
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	473
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	1,574
HTC_TST_DSD	Service Delivery Point (Facility): VCT	1,103
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	0
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	0
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
GEND_GBV_DSD	Number of people receiving post-GBV care	110
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	44
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	66
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	60
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,674
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	135
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,025
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	136
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,378



TX_CURR_DSD	Sum of Aggregated Age/Sex <15	271
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,403
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,674
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	525
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	22
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	138
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	18
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	347
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	525
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,387
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,734
TX_PVLS_DSD	Numerator: Indication: Routine	1,110
TX_PVLS_DSD	Numerator: Indication: Targeted	277
TX_PVLS_DSD	Denominator: Indication: Routine	1,387
TX_PVLS_DSD	Denominator: Indication: Targeted	347
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	70
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	531
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	71
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	715
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	88
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	665
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	88
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	893
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	150
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	173



	period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	47
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	86
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	55
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	99
HRH_PRE	Number of new HCW who graduated from a pre-service	126



	training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	
HRH_PRE	By Graduates: Doctors	126
HRH_PRE	Sum of Graduates disaggregates	126

**Implementing Mechanism Details**

<b>Mechanism ID: 10559</b>	<b>Mechanism Name: Peer-to-Peer Capacity Building of Ministries of Health in Public Sector HIV Program Management</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Alliance of State and Territorial AIDS Directors	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,050,158</b>	
<b>Applied Pipeline Amount: 64,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,114,158</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,050,158

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	10559
<b>Mechanism Name:</b>	Peer-to-Peer Capacity Building of Ministries of Health in Public Sector HIV Program Management
<b>Prime Partner Name:</b>	National Alliance of State and Territorial AIDS Directors





Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	265,298	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	124,678	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	191,812	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	468,370	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 10564</b>	<b>Mechanism Name: HIV Prevention for Vulnerable Adolescent Girls</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 150,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 150,000</b>	
Funding Source	Funding Amount
GHP-State	150,000



### Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Operation Research

### Budget Code Information

<b>Mechanism ID:</b> 10564 <b>Mechanism Name:</b> HIV Prevention for Vulnerable Adolescent Girls <b>Prime Partner Name:</b> Population Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	150,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 10599	<b>Mechanism Name:</b> Twinning Initiative
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 900,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 900,000</b>	



Funding Source	Funding Amount
GHP-State	900,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 10599			
<b>Mechanism Name:</b> Twinning Initiative			
<b>Prime Partner Name:</b> American International Health Alliance Twinning Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	900,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	203
HRH_PRE	By Graduates: Doctors	12
HRH_PRE	By Graduates: Other	191
HRH_PRE	Sum of Graduates disaggreagtes	203

### Implementing Mechanism Details

<b>Mechanism ID:</b> 10601	<b>Mechanism Name:</b> G2G-TBD - Addis Ababa University - Strengthening HIV/AIDS, STI & TB Prevention, Care & Treatment Activities
----------------------------	--



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Addis Ababa University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 504,892</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 504,892</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	504,892

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	81,872
Renovation	27,239
Gender: GBV	6,500
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



### Budget Code Information

<b>Mechanism ID:</b>	10601		
<b>Mechanism Name:</b>	G2G-TBD - Addis Ababa University - Strengthening HIV/AIDS, STI & TB		
<b>Prime Partner Name:</b>	Prevention, Care & Treatment Activities		
	Addis Ababa University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	81,872	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	16,904	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	328,964	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	77,152	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,000
PP_PREV_DSD	Total number of people in the target population	1,200
GEND_GBV_DSD	Number of people receiving post-GBV care	50
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	20
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	30
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	27
TX_CURR_DSD	Number of adults and children receiving antiretroviral	4,267



	therapy (ART)	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	329
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,382
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	316
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,240
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	645
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,622
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,267
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	471
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	52
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	135
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	94
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	190
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	471
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	2,213
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,766
TX_PVLS_DSD	Numerator: Indication: Routine	1,770
TX_PVLS_DSD	Numerator: Indication: Targeted	443
TX_PVLS_DSD	Denominator: Indication: Routine	2,213
TX_PVLS_DSD	Denominator: Indication: Targeted	553
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	171
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	716
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	164
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	1,162
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	213
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	896
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	205



TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,452
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	279
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	323
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	88
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	160
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	102
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total	186



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	215
HRH_PRE	By Graduates: Doctors	215
HRH_PRE	Sum of Graduates disaggreagtes	215

**Implementing Mechanism Details**

<b>Mechanism ID: 10603</b>	<b>Mechanism Name: Supporting Laboratory Training and Quality Improvement for Diagnosis and Laboratory Monitoring of HIV/AIDS Patients in Resource-Limited Countries (ASCP)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society of Clinical Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)





**Budget Code Information**

<b>Mechanism ID:</b>	<b>10603</b>		
<b>Mechanism Name:</b>	<b>Supporting Laboratory Training and Quality Improvement for Diagnosis and Laboratory Monitoring of HIV/AIDS Patients in Resource-Limited</b>		
<b>Prime Partner Name:</b>	<b>Countries (ASCP) American Society of Clinical Pathology</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 10604</b>	<b>Mechanism Name: Capacity building assistance to support sustainable HIV/AIDS integrated laboratory program development</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 143,859</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 143,859</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	143,859

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b>	10604		
<b>Mechanism Name:</b>	Capacity building assistance to support sustainable HIV/AIDS		
<b>Prime Partner Name:</b>	integrated laboratory program development Association of Public Health Laboratories		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	143,859	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 10663</b>	<b>Mechanism Name: Capacity building assistance for global HIV/AIDS microbiological Lab program development</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	10663		
<b>Mechanism Name:</b>	Capacity building assistance for global HIV/AIDS microbiological Lab program development		
<b>Prime Partner Name:</b>	American Society for Microbiology		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 11033</b>	<b>Mechanism Name: Strengthening PEPFAR Visibility</b>
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 350,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 350,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	350,000



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	11033		
<b>Mechanism Name:</b>	Strengthening PEPFAR Visibility		
<b>Prime Partner Name:</b>	U.S. Department of State		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	350,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 11036</b>	<b>Mechanism Name: Comprehensive prevention and response program to HIV/AIDS in Adi Harush, Shimmelba, MyAyni Refugee camps</b>
Funding Agency: State/PRM	Procurement Type: Cooperative Agreement
Prime Partner Name: International Rescue Committee	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	



Funding Source	Funding Amount
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	11036		
<b>Mechanism Name:</b>	Comprehensive prevention and response program to HIV/AIDS in Adi Harush, Shimelba, MyAyni Refugee camps		
<b>Prime Partner Name:</b>	International Rescue Committee		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 11040</b>	<b>Mechanism Name: HIV in Refugee Camps</b>
Funding Agency: State/PRM	Procurement Type: Grant
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,000,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,000,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,000,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 11040</b>			
<b>Mechanism Name: HIV in Refugee Camps</b>			
<b>Prime Partner Name: United Nations High Commissioner for Refugees</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	208,911	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	44,457	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	4,344	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HVSI	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	122,400	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	309,750	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	605,114	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	197,115	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	439,846	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	18,063	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,211
PMTCT_ART_DSD	New on ART	118
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	85
PMTCT_STAT_DSD	Number of pregnant women with known HIV status	16,211

	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	17,502
PMTCT_STAT_DSD	By: Known positives at entry	71
PMTCT_STAT_DSD	By: Number of new positives identified	99
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	170
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	700
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	40
VMMC_CIRC_DSD	By Age: 15-19	260
VMMC_CIRC_DSD	By Age: 20-24	330
VMMC_CIRC_DSD	By Age: 25-29	120
VMMC_CIRC_DSD	By Age: 30-49	0
VMMC_CIRC_DSD	By Age: 50+	0
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	630
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	750
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	640
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,000
PP_PREV_DSD	Total number of people in the target population	554,286
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	315
KP_PREV_DSD	Total estimated number of key population in the catchment area	593
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with	310





	individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	583
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	36,334
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	791
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,890
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	791
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	27,230
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,582
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	34,120
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	35,702
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	41
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	206
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	49
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	678
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	6,700
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	6,700
HTC_TST_DSD	Service Delivery Point (Facility): VCT	17,024
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	250
GEND_GBV_DSD	Number of people receiving post-GBV care	60
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence	30



	(Other Post-GBV Care)	
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	30
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	30
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,562
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	6
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	35
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	6
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	43
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,066
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	66
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	346
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	66
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,121
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	132
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,467
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,599
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	282
TX_NEW_DSD	By Age/Sex: 20-24 Female	1
TX_NEW_DSD	Sum of Age/Sex disaggregates	1
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	18
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	51
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	23
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	104
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	196
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	20
TX_RET_DSD	Number of adults and children who are still alive and on	337



	treatment at 12 months after initiating ART	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	377
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2

**Implementing Mechanism Details**

<b>Mechanism ID: 12306</b>	<b>Mechanism Name: Increasing Access of VCT services to hot spot urban-rural setting and improving care and support at the community level in Federal Democratic Republic of Ethiopia under the President's Emergency Plan for AIDS</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Organization for Social Services for AIDS (OSSA)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,874,346</b>	
---	--



<b>Applied Pipeline Amount: 556,710</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,431,056</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,874,346

**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Policy, Tools, and Service Delivery	71,929
---	--------

**Budget Code Information**

<b>Mechanism ID:</b>	12306		
<b>Mechanism Name:</b>	Increasing Access of VCT services to hot spot urban-rural setting and improving care and support at the community level in Federal Democratic Republic of Ethiopia under the President's Emergency Plan for AIDS		
<b>Prime Partner Name:</b>	Organization for Social Services for AIDS (OSSA)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	719,294	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	19,264	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	1,135,788	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	70,000
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	13,504
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	20,095
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12,601
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	23,800
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	26,105
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	43,895
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	70,000
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	305
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,178
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	142
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,426
HTC_TST_DSD	Service Delivery Point (Community): Index testing	70,000

### Implementing Mechanism Details

<b>Mechanism ID: 12307</b>	<b>Mechanism Name: Prevention of Cervical Cancer among HIV positive women in the Federal Democratic Republic of Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Pathfinder International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12307		
<b>Mechanism Name:</b>	Prevention of Cervical Cancer among HIV positive women in the Federal Democratic Republic of Ethiopia		
<b>Prime Partner Name:</b>	Pathfinder International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 12313</b>	<b>Mechanism Name: Support for the Greater Involvement of People Living with HIV/AIDS (GIPA) in the Federal Democratic Republic of Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: NETWORK OF NETWORKS OF ETHIOPIANS LIVING WITH HIV/AIDS (NEP+)	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12313		
<b>Mechanism Name:</b>	Support for the Greater Involvement of People Living with HIV/AIDS (GIPA) in the Federal Democratic Republic of Ethiopia		
<b>Prime Partner Name:</b>	NETWORK OF NETWORKS OF ETHIOPIANS LIVING WITH HIV/AIDS (NEP+)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 12314</b>	<b>Mechanism Name: Expansion and Strengthening of the PMTCT Services in the</b>
----------------------------	---

Approved



	<b>Private Health Facilities in Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ethiopian Society of Obstetricians and Gynecologists	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	12314		
<b>Mechanism Name:</b>	Expansion and Strengthening of the PMTCT Services in the Private Health Facilities in Ethiopia		
<b>Prime Partner Name:</b>	Ethiopian Society of Obstetricians and Gynecologists		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details





<b>Mechanism ID: 12319</b>	<b>Mechanism Name: Integrated HIV Prevention Program for Federal Police Force of Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Federal Police, Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 1,123,518</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,123,518</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,123,518

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	34,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Food and Nutrition: Policy, Tools, and Service Delivery	6,261
Human Resources for Health	43,344
Renovation	33,801



**Budget Code Information**

<b>Mechanism ID:</b> 12319			
<b>Mechanism Name:</b> Integrated HIV Prevention Program for Federal Police Force of Ethiopia			
<b>Prime Partner Name:</b> Federal Police, Ethiopia			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	48,160	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	86,688	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	10,403	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	19,264	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	40,443	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	43,344	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	62,608	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	390,682	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	21,376	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	387,788	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	12,762	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,464
PMTCT_ART_DSD	New on ART	15
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	28
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,464
PMTCT_STAT_DSD	Number of new ANC and L&D clients	1,541
PMTCT_STAT_DSD	By: Known positives at entry	30
PMTCT_STAT_DSD	By: Number of new positives identified	15
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	45
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	22,805
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	20,890
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,915



HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,000
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,000
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	18,000
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	20,000
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	1,000
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	2,000
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	2,000
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	6,966
HTC_TST_TA	Service Delivery Point (Facility): VCT	5,000
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	1,434
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	600
HTC_TST_TA	Service Delivery Point (Facility): Index testing	1,000
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	224
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	229
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	171



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	46
GEND_GBV_DSD	Number of people receiving post-GBV care	50
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	20
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	30
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	27
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	56
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	56
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	45
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11

TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	2,545
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	63
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1,544
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	53
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	885
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	255
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,782
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	534
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	713
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	764
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	31
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	8
PMTCT_EID_DSD	Sum of Infant Age disaggregates	39
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
PMTCT_EID_TA	Number of infants with a positive virological test result	0



	within 2 months of birth	
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,828
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	69
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,717
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	57
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	985
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	126
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,702
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,828
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	246
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	7
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	147
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	7
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	85
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	246
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,528
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,697
TX_PVLS_DSD	Numerator: Indication: Routine	1,527
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	1,528
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	38
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	927
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	31



TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	532
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	42
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,030
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	34
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	591
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	174
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	205
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	111
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	55
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	132
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the	6





	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	62
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	5
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	5
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	3
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	3
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1



LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	5
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	3
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	135
HRH_PRE	By Graduates: Nurses	55
HRH_PRE	By Graduates: Other	80
HRH_PRE	Sum of Graduates disaggreagtes	135

### Implementing Mechanism Details

<b>Mechanism ID: 12321</b>	<b>Mechanism Name: HIV/AIDS Antiretroviral therapy implementation support through local universities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Gondar University	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 538,240</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 538,240</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	538,240

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	134,268
Gender: GBV	6,500
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b> 12321
----------------------------



<b>Mechanism Name:</b> HIV/AIDS Antiretroviral therapy implementation support through local			
<b>Prime Partner Name:</b> universities			
<b>Gondar University</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	134,268	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	28,445	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	289,802	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	85,725	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Total number of people in the target population	2,000
GEND_GB_V_DSD	Number of people receiving post-GBV care	50
GEND_GB_V_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	20
GEND_GB_V_DSD	By type of service: Sexual Violence (Post-Rape Care)	30
GEND_GB_V_DSD	By PEP service provision (related to sexual violence services provided)	27
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,985
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	240
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,824
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	292
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,629



TX_CURR_DSD	Sum of Aggregated Age/Sex <15	532
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	7,453
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,985
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	786
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	50
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	242
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	64
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	430
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	786
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	4,141
TX_PVLS_DSD	Numerator: Indication: Routine	3,313
TX_PVLS_DSD	Numerator: Indication: Targeted	828
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	124
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	1,465
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	151
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	2,401
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	240
HRH_PRE	By Graduates: Doctors	240
HRH_PRE	Sum of Graduates disaggreagtes	240

**Implementing Mechanism Details**

<b>Mechanism ID: 13053</b>	<b>Mechanism Name: Strengthening Integration of PMTCT/STIs/HTC with Reproductive Health Services at Family Guidance Association's of Ethiopia Clinics and Youth Centers</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Family Guidance Association of Ethiopia	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13053		
<b>Mechanism Name:</b>	Strengthening Integration of PMTCT/STIs/HTC with Reproductive Health Services at Family Guidance Association's of Ethiopia Clinics and Youth		
<b>Prime Partner Name:</b>	Centers Family Guidance Association of Ethiopia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Approved



Treatment	HTXS	0	0
-----------	------	---	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13158</b>	<b>Mechanism Name: Supporting the National Blood Transfusion services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Federal Ministry of Health, Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 1,425,068</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,425,068</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,425,068

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13158			
<b>Mechanism Name:</b>	Supporting the National Blood Transfusion services		
<b>Prime Partner Name:</b>	Federal Ministry of Health, Ethiopia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HMBL	1,425,068	0
------------	------	-----------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13254</b>	<b>Mechanism Name: Technical Assistance in support of HIV prevention, care, and treatment program and other infectious diseases</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tulane University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13254
<b>Mechanism Name:</b>	Technical Assistance in support of HIV prevention, care, and treatment program and other infectious diseases
<b>Prime Partner Name:</b>	Tulane University





Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13456</b>	<b>Mechanism Name: Ethiopian Health Management Initiative (EHMI)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinton Health Access Initiative	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 13456			
<b>Mechanism Name:</b> Ethiopian Health Management Initiative (EHMI)			
<b>Prime Partner Name:</b> Clinton Health Access Initiative			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 13530	<b>Mechanism Name:</b> Technical assistance to build host government capacity
Funding Agency: HHS/CDC	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 96,320</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 96,320</b>	
Funding Source	Funding Amount
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b>	13530		
<b>Mechanism Name:</b>	Technical assistance to build host government capacity		
<b>Prime Partner Name:</b>	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13597</b>	<b>Mechanism Name: Continued Education Health Workers</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mayo Clinic	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 13597</b>			
<b>Mechanism Name: Continued Education Health Workers</b>			
<b>Prime Partner Name: Mayo Clinic</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13770</b>	<b>Mechanism Name: Support to GOE Regional Health Bureau in Harari</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Harari Regional Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 1,132,139</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,132,139</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,132,139

**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Policy, Tools, and Service Delivery	10,643
Renovation	98,713
Key Populations: FSW	4,582
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	14,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b> 13770			
<b>Mechanism Name:</b> Support to GOE Regional Health Bureau in Harari			
<b>Prime Partner Name:</b> Harari Regional Health Bureau			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	81,872	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	96,320	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	34,290	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	43,344	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	24,796	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	38,528	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	12,825	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	40,267	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	11,455	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	75,840	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	642,598	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	30,004	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	13,055
PMTCT_ART_DSD	New on ART	29
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	78
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	13,055
PMTCT_STAT_DSD	Number of new ANC and L&D clients	14,063
PMTCT_STAT_DSD	By: Known positives at entry	96
PMTCT_STAT_DSD	By: Number of new positives identified	20



PMTCT_STAT_DSD	Sum of Positives Status disaggregates	116
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,096
PP_PREV_DSD	Total number of people in the target population	1,316
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	360
KP_PREV_DSD	Total estimated number of key population in the catchment area	582
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	360
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	582
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	40,347
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,701
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,630
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,634
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	25,382
HTC_TST_TA	Sum of Aggregated Age/Sex <15	3,335
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	37,012
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	40,347
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15	19





	Male	
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	91
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	15
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	189
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	3,085
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	11,822
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	0
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	2,052
HTC_TST_TA	Service Delivery Point (Facility): VCT	6,424
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	14,649
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	2,315
HTC_TST_TA	Service Delivery Point (Facility): Index testing	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	537
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	551
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	43
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	259
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	31
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	204
GEND_GBV_DSD	Number of people receiving post-GBV care	50



GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	20
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	30
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	27
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	67
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	67
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	32
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	26
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,584
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	149
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1,118
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	141
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	2,176



TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	359
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	252
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	74
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	100
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	78
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	81
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	21
PMTCT_EID_DSD	Sum of Infant Age disaggregates	102
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	1
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,716
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	44
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	605
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	51
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,016
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	95
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,621
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,716
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	169
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	10
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	56
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	9
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	94



TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	169
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	891
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,114
TX_PVLS_DSD	Numerator: Indication: Routine	713
TX_PVLS_DSD	Numerator: Indication: Targeted	178
TX_PVLS_DSD	Denominator: Indication: Routine	892
TX_PVLS_DSD	Denominator: Indication: Targeted	222
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	24
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	313
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	27
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	527
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	29
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	390
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	35
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	660
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	99
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	109
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	33
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on	4



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	58
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	64
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	9
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	9
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	3
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	3
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable	3



	successful passing criteria in this PT program	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	9
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	3
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories	1



	that achieve acceptable successful passing criteria in this PT program	
--	--	--

**Implementing Mechanism Details**

<b>Mechanism ID: 13794</b>	<b>Mechanism Name: Oromia Regional Health Bureau HIV/AIDS program</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Oromia Health Bureau, Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 8,908,463</b>	
<b>Applied Pipeline Amount: 480,600</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 9,389,063</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	8,908,463

**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Policy, Tools, and Service Delivery	137,145
Renovation	1,791,000
Motor Vehicles: Purchased	400,000
Key Populations: FSW	55,845
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other



	commodities essential to core HIV services for SWs
Gender: GBV	308,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	13794		
<b>Mechanism Name:</b>	Oromia Regional Health Bureau HIV/AIDS program		
<b>Prime Partner Name:</b>	Oromia Health Bureau, Ethiopia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,054,964	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	374,033	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	165,198	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	HLAB	156,694	0





Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	179,652	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	90,076	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	48,581	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	99,613	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	94,612	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	791,761	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,903,811	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	949,468	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	474,996



	their results)	
PMTCT_ART_DSD	New on ART	1,559
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,821
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,257
PMTCT_ART_TA	New on ART	45
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	74
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	474,996
PMTCT_STAT_DSD	Number of new ANC and L&D clients	513,949
PMTCT_STAT_DSD	By: Known positives at entry	1,917
PMTCT_STAT_DSD	By: Number of new positives identified	1,602
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	3,519
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,257
PMTCT_STAT_TA	Number of new ANC and L&D clients	8,773
PMTCT_STAT_TA	By: Known positives at entry	69
PMTCT_STAT_TA	By: Number of new positives identified	39
PMTCT_STAT_TA	Sum of Positives Status disaggregates	108
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	25,923
PP_PREV_DSD	Total number of people in the target population	31,119
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,900
KP_PREV_DSD	Total estimated number of key population in the catchment area	22,371
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with	2,900



	individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	22,371
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,931
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	312
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	594
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	300
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,725
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	612
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,319
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,931
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	3
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	10
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	211
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	808
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	140
HTC_TST_DSD	Service Delivery Point (Facility): VCT	439



HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	1,175
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	158
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,002,028
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	163,836
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	593,364
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	157,393
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,087,425
HTC_TST_TA	Sum of Aggregated Age/Sex <15	321,229
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	1,680,789
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	2,002,018
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	1,818
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	7,487
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	1,519
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	14,674
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	1,236
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	4,735
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	0
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	821
HTC_TST_TA	Service Delivery Point (Facility): VCT	2,574
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0



HTC_TST_TA	Service Delivery Point (Facility): PMTCT	6,892
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	926
HTC_TST_TA	Service Delivery Point (Facility): Index testing	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	15,277
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	16,404
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,240
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,436
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	916
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,887
GEND_GBV_DSD	Number of people receiving post-GBV care	865
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	364
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	501
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	459
GEND_GBV_TA	Number of people receiving post-GBV care	306
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	125
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	181
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	165
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,239
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,450
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	89
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	738
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	62



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	550
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	112,622
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	5,316
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	39,036
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	4,998
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	63,268
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	11,269
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	7,897
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	2,376
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	4,013
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	2,371
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	435
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	20
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	142
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	18
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	255
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	44
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	31
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	9

TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	13
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	9
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,614
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	668
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,282
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	58
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	22
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	80
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	20
PMTCT_EID_TA	Sum of Infant Age disaggregates	100
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	2
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	1
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	120,721
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,667
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	41,851
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	5,314
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	67,783
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	10,981
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	109,634
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	120,615
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	500





TX_CURR_TA	Aggregated Age/Sex: <15 Male	22
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	164
TX_CURR_TA	Aggregated Age/Sex: <15 Female	21
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	293
TX_CURR_TA	Sum of Aggregated Age/Sex <15	43
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	457
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	500
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	25,878
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2,109
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	7,833
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,801
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	14,114
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	25,857
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	59
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	2
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	14
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	2
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	26
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	44
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	61,179
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	76,467
TX_PVLS_DSD	Numerator: Indication: Routine	48,944
TX_PVLS_DSD	Numerator: Indication: Targeted	12,235
TX_PVLS_DSD	Denominator: Indication: Routine	61,187
TX_PVLS_DSD	Denominator: Indication: Targeted	15,282
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	2,890



TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	21,214
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,727
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	34,361
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3,597
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	26,535
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	3,378
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	42,960
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	49
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	62
TX_PVLS_TA	Numerator: Indication: Routine	40
TX_PVLS_TA	Numerator: Indication: Targeted	9
TX_PVLS_TA	Denominator: Indication: Routine	49
TX_PVLS_TA	Denominator: Indication: Targeted	13
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	2
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	16
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	2
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	29
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	3
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	19
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	3
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	37
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,354
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,364
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and	16



	children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	524
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,573
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	412
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,732
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	539
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,906
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	457
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	5,285



	stopped ART, and those lost to follow-up)	
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	11
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults	0



	and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	0



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0



TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	233
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	233
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in	233



	this PT program	
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	74
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	57
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	57
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	4
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	4
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	4
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	4
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	233
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	46
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	46
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	32
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	4
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	4





LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	2
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	2
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2

**Implementing Mechanism Details**

<b>Mechanism ID: 13928</b>	<b>Mechanism Name: Addis Ababa Regional HIV/AIDS Prevention and Control Office</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Addis Ababa HIV/AIDS Prevention and Control Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13928
<b>Mechanism Name:</b>	Addis Ababa Regional HIV/AIDS Prevention and Control Office
<b>Prime Partner Name:</b>	Addis Ababa HIV/AIDS Prevention and Control Office



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13929</b>	<b>Mechanism Name: Dire-Dawa Health Bureau HIV/AIDS program</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Dire Dawa City Administration Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 1,280,554</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,280,554</b>	
Funding Source	Funding Amount
GHP-State	1,280,554

### Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	13,714
Key Populations: FSW	7,040
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on



	sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	14,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Motor Vehicles: Purchased	80,000

**Budget Code Information**

<b>Mechanism ID:</b>	13929		
<b>Mechanism Name:</b>	Dire-Dawa Health Bureau HIV/AIDS program		
<b>Prime Partner Name:</b>	Dire Dawa City Administration Health Bureau		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	105,496	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	115,087	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	21,431	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	43,344	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	24,796	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	38,528	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	12,654	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	42,381	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	17,600	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	52,475	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	748,469	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDX	58,293	0
-----------	-----	--------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,297
PMTCT_ART_DSD	New on ART	68
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	142
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	980
PMTCT_ART_TA	New on ART	1
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	17
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,297
PMTCT_STAT_DSD	Number of new ANC and L&D clients	20,313
PMTCT_STAT_DSD	By: Known positives at entry	151
PMTCT_STAT_DSD	By: Number of new positives identified	68
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	219
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	980
PMTCT_STAT_TA	Number of new ANC and L&D clients	1,044
PMTCT_STAT_TA	By: Known positives at entry	19
PMTCT_STAT_TA	By: Number of new positives identified	2
PMTCT_STAT_TA	Sum of Positives Status disaggregates	21
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,545



PP_PREV_DSD	Total number of people in the target population	3,052
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	450
KP_PREV_DSD	Total estimated number of key population in the catchment area	1,798
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	450
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	1,798
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	79,177
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,044
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	28,112
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,925
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	45,096
HTC_TST_TA	Sum of Aggregated Age/Sex <15	5,969
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	73,208
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	79,177
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	44
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	276
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15	43



	Female	
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	610
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	2,546
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	36,259
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	0
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	4,797
HTC_TST_TA	Service Delivery Point (Facility): VCT	15,010
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	19,146
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	1,419
HTC_TST_TA	Service Delivery Point (Facility): Index testing	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,420
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,449
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	122
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	674
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	91
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	533
GEND_GBV_DSD	Number of people receiving post-GBV care	105
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	42
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	63
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	59



TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	199
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	199
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	19
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	96
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	72
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	6,908
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	336
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,219
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	214
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	4,139
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	691
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	483
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	147



TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	193
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	143
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	164
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	41
PMTCT_EID_DSD	Sum of Infant Age disaggregates	205
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	4
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	22
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	5
PMTCT_EID_TA	Sum of Infant Age disaggregates	27
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,694
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	374
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,470
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	237
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,613
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	611
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	7,083
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,694
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,068



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	59
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	328
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	49
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	632
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,068
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	3,989
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	4,987
TX_PVLS_DSD	Numerator: Indication: Routine	3,191
TX_PVLS_DSD	Numerator: Indication: Targeted	798
TX_PVLS_DSD	Denominator: Indication: Routine	3,991
TX_PVLS_DSD	Denominator: Indication: Targeted	996
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	196
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	1,277
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	126
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	2,390
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	243
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,598
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	157
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	2,989
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	588
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	642
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	35



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	186
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	338
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	38
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	203
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	32
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	369
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	12
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	12
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in	12



	this PT program	
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	5
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	4
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	12
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	4
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0



LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0

**Implementing Mechanism Details**

<b>Mechanism ID: 13931</b>		<b>Mechanism Name: Federal HAPCO Support</b>	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: Federal HAPCO			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
G2G: Yes		Managing Agency: HHS/CDC	

<b>Total All Funding Sources: 182,880</b>	
<b>Applied Pipeline Amount: 196,320</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 379,200</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	182,880

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 13931</b>			
<b>Mechanism Name: Federal HAPCO Support</b>			
<b>Prime Partner Name: Federal HAPCO</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	25,200	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	51,347	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	106,333	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13932</b>	<b>Mechanism Name: HIV/AIDS Antiretroviral therapy program implementation support through local universities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Haramaya University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 422,868</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 422,868</b>	
Funding Source	Funding Amount
GHP-State	422,868

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	81,872
Gender: GBV	6,500
Focus Area:	GBV Prevention



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	13932		
<b>Mechanism Name:</b>	HIV/AIDS Antiretroviral therapy program implementation support through local universities		
<b>Prime Partner Name:</b>	Haramaya University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	81,872	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	16,904	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	289,802	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	34,290	0



## Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	450
PP_PREV_DSD	Total number of people in the target population	680
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	200
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	250
GEND_GBV_DSD	Number of people receiving post-GBV care	50
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	20
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	30
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	27
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,274
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,409
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	641
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	104
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	120
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,513
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	761
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,274
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	223
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	18
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	67
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	11
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	137
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	233
TX_PVLS_DSD	Number of adults and pediatric patients on ART with	1,179





	suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,479
TX_PVLS_DSD	Numerator: Indication: Routine	943
TX_PVLS_DSD	Numerator: Indication: Targeted	236
TX_PVLS_DSD	Denominator: Indication: Routine	1,179
TX_PVLS_DSD	Denominator: Indication: Targeted	295
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	62
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	333
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	54
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	730
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	78
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	415
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	68
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	913
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	129
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	141
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	41
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number	74



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	45
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	81
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	143
HRH_PRE	By Graduates: Doctors	143
HRH_PRE	Sum of Graduates disaggreagtes	143

**Implementing Mechanism Details**

<b>Mechanism ID: 13933</b>	<b>Mechanism Name: Strengthening Human Resources for Health through increased capacity of the Ethiopian Medical Association</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ethiopian Medical Association	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 187,306</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 187,306</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	187,306

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13933		
<b>Mechanism Name:</b>	Strengthening Human Resources for Health through increased capacity of the Ethiopian Medical Association		
<b>Prime Partner Name:</b>	Ethiopian Medical Association		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	67,424	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	119,882	0

### Implementing Mechanism Indicator Information

(No data provided.)



### Implementing Mechanism Details

<b>Mechanism ID: 13934</b>	<b>Mechanism Name: Strengthening local ownership for sustainable provision of HIV/AIDS services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Addis Ababa Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 5,372,237</b>	
<b>Applied Pipeline Amount: 200,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 5,572,237</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,372,237

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	81,872
Food and Nutrition: Policy, Tools, and Service Delivery	87,898
Renovation	689,500
Motor Vehicles: Purchased	120,000
Key Populations: FSW	41,621
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs



Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	30,300
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	13934		
<b>Mechanism Name:</b>	Strengthening local ownership for sustainable provision of HIV/AIDS services		
<b>Prime Partner Name:</b>	Addis Ababa Health Bureau		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	676,136	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	143,859	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	115,231	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	HLAB	46,320	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	83,362	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	36,302	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	17,098	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	74,128	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	64,053	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	460,348	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,228,342	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	427,058	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	73,521



	their results)	
PMTCT_ART_DSD	New on ART	1,080
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,560
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	31,646
PMTCT_ART_TA	New on ART	248
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	675
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	73,521
PMTCT_STAT_DSD	Number of new ANC and L&D clients	75,843
PMTCT_STAT_DSD	By: Known positives at entry	1,714
PMTCT_STAT_DSD	By: Number of new positives identified	1,098
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2,812
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	31,646
PMTCT_STAT_TA	Number of new ANC and L&D clients	33,503
PMTCT_STAT_TA	By: Known positives at entry	676
PMTCT_STAT_TA	By: Number of new positives identified	280
PMTCT_STAT_TA	Sum of Positives Status disaggregates	956
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	191
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	16,671
PP_PREV_DSD	Total number of people in the target population	19,703
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,400
KP_PREV_DSD	Total estimated number of key population in the catchment area	3,400



KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,400
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	3,400
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	237,128
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,868
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	77,242
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,677
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	150,341
HTC_TST_TA	Sum of Aggregated Age/Sex <15	9,545
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	227,583
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	237,128
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	482
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,813
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	436
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	6,634
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	18,973
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	72,728
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	211
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	12,636





HTC_TST_TA	Service Delivery Point (Facility): VCT	39,531
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	79,031
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	14,228
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	275
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	281
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	22
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	132
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	17
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	104
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	7,924
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	7,939
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	633
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,792
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	472
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with	3,007



	documented HIV status, during the reporting period)	
GEND_GBVDSD	Number of people receiving post-GBV care	978
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	390
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	586
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	522
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,226
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,226
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	173
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,075
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	133
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	845
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	75,326
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	4,045
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	24,921



TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,998
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	43,335
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	7,534
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	5,280
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,586
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2,111
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	1,583
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,249
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	566
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,815
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	56
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	33
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	543
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	134
PMTCT_EID_TA	Sum of Infant Age disaggregates	677
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	10
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	2
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	77,948
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	4,178
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	25,821
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,961



TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	44,988
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	7,139
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	70,809
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	77,948
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	12,224
TX_CURR_TA	Aggregated Age/Sex: <15 Male	74
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	6,006
TX_CURR_TA	Aggregated Age/Sex: <15 Female	61
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	6,083
TX_CURR_TA	Sum of Aggregated Age/Sex <15	135
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	12,089
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	12,224
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,242
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	661
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,998
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	597
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,984
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,240
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,606
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	42
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	1,070
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	26
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,468
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	2,606
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	40,370
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record	50,196



	and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Numerator: Indication: Routine	32,294
TX_PVLS_DSD	Numerator: Indication: Targeted	8,076
TX_PVLS_DSD	Denominator: Indication: Routine	40,154
TX_PVLS_DSD	Denominator: Indication: Targeted	10,968
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	2,150
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	13,332
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,556
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	23,266
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,676
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	16,666
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,944
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	28,610
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,501
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	7,334
TX_PVLS_TA	Numerator: Indication: Routine	4,951
TX_PVLS_TA	Numerator: Indication: Targeted	550
TX_PVLS_TA	Denominator: Indication: Routine	6,601
TX_PVLS_TA	Denominator: Indication: Targeted	733
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	32
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	2,705
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	26
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	2,738
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	45
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	3,600
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	39
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	3,651



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,297
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,139
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	318
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,663
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	268
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,048
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	369
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,930
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	311
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	3,529



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	816
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	950
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	50
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	257
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	42
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	467
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	58
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	293
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	49



	stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	541
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	85
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	85
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	85
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	19
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	12
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	12
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	3
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	3
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	3
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	3
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	85





LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	12
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	12
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	5
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	4
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	2
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	2
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2

**Implementing Mechanism Details**

<b>Mechanism ID: 13948</b>	<b>Mechanism Name: Nursing Capacity Building Program</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 135,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 135,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	135,000



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13948			
<b>Mechanism Name:</b> Nursing Capacity Building Program			
<b>Prime Partner Name:</b> Columbia University Mailman School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	135,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 14209	<b>Mechanism Name:</b> Strengthening Human Resources for Health
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 1,500,000	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 1,500,000	
Funding Source	Funding Amount
GHP-State	1,500,000



### Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,200,000
----------------------------	-----------

### Budget Code Information

<b>Mechanism ID:</b>	14209		
<b>Mechanism Name:</b>	Strengthening Human Resources for Health		
<b>Prime Partner Name:</b>	JHPIEGO		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	1,500,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	8,271
HRH_PRE	By Graduates: Doctors	0
HRH_PRE	By Graduates: Nurses	0
HRH_PRE	By Graduates: Midwives	3,038
HRH_PRE	By Graduates: Social service workers	0
HRH_PRE	By Graduates: Laboratory professionals	0
HRH_PRE	By Graduates: Other	5,233
HRH_PRE	Sum of Graduates disaggreagtes	8,271

### Implementing Mechanism Details



<b>Mechanism ID: 14210</b>	<b>Mechanism Name: Strengthening Ethiopia's Urban Health Program</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 971,706</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 971,706</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	971,706

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	120,000
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID: 14210</b>			
<b>Mechanism Name: Strengthening Ethiopia's Urban Health Program</b>			
<b>Prime Partner Name: John Snow, Inc.</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	91,706	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	500,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	80,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0
PP_PREV_TA	Total number of people in the target population	0
PP_PREV_TA	Aggregated Age/sex: <15 Male	0
PP_PREV_TA	Aggregated Age/sex: 15+ Male	0
PP_PREV_TA	Aggregated Age/sex: <15 Female	0
PP_PREV_TA	Aggregated Age/sex: 15+ Female	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	9,072
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	135
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,587
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	313
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,037
HTC_TST_TA	Sum of Aggregated Age/Sex <15	448
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	8,624
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	9,072
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	1



HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	58
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	9
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	172
HTC_TST_TA	Service Delivery Point (Community): Homebased testing	9,072

### Implementing Mechanism Details

<b>Mechanism ID: 14215</b>	<b>Mechanism Name: Food and Nutrition Technical Assistance III</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 420,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 420,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	420,000

### Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	150,000
Gender: Gender Equality	30,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

### Budget Code Information

<b>Mechanism ID:</b>	14215		
<b>Mechanism Name:</b>	Food and Nutrition Technical Assistance III		
<b>Prime Partner Name:</b>	FHI 360		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	169,853	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	33,971	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	30,882	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	185,294	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 14217	<b>Mechanism Name:</b> Urban HIV/AIDS Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Food Program	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,595,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,595,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,595,000

**Cross-Cutting Budget Attribution(s)**

Economic Strengthening	166,000
Food and Nutrition: Commodities	444,000
Food and Nutrition: Policy, Tools, and Service Delivery	499,000

**Budget Code Information**

<b>Mechanism ID:</b>	14217		
<b>Mechanism Name:</b>	Urban HIV/AIDS Project		
<b>Prime Partner Name:</b>	World Food Program		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	25,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	110,000	0





Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	260,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14228</b>	<b>Mechanism Name: MULU Prevention Program for At-Risk Populations I (MULU I)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 8,577,278</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 8,577,278</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	8,577,278

### Cross-Cutting Budget Attribution(s)

Condom programming	150,000
Economic Strengthening	120,000
Gender: GBV	60,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting



	positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	4,500,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs

**Budget Code Information**

<b>Mechanism ID:</b> 14228
----------------------------



<b>Mechanism Name:</b>	<b>MULU Prevention Program for At-Risk Populations I (MULU I)</b>		
<b>Prime Partner Name:</b>	<b>Population Services International</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	400,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	905,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	6,410,278	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	862,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	51,776
PP_PREV_DSD	Total number of people in the target population	189,864
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	38,045
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	13,731
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	49,529
KP_PREV_DSD	Total estimated number of key population in the catchment area	74,363
KP_PREV_DSD	By key population type: Female sex workers (FSW)	49,529



	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	74,363
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	113,230
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	35,054
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	64
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	78,110
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	66
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	113,164
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	113,230
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,095
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,436
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	31,769
HTC_TST_DSD	Service Delivery Point (Community): Other	44,662
HTC_TST_DSD	Service Delivery Point (Facility): VCT	36,649

## Implementing Mechanism Details



<b>Mechanism ID: 14230</b>	<b>Mechanism Name: MULU Prevention Program for At-Risk Populations in Workplace (MULU II)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Learning	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,800,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,800,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,800,000

### Cross-Cutting Budget Attribution(s)

Condom programming	104,326
Gender: GBV	37,500
Focus Area:	GBV Prevention
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	12,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building
Key Populations: FSW	46,385
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Monitoring and evaluation of SW programs



### Budget Code Information

<b>Mechanism ID:</b>	14230		
<b>Mechanism Name:</b>	MULU Prevention Program for At-Risk Populations in Workplace (MULU		
<b>Prime Partner Name:</b>	II) World Learning		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	450,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	1,950,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	250,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	190,731
PP_PREV_DSD	Total number of people in the target population	784,192
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	172,228
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	18,503
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,800
KP_PREV_DSD	Total estimated number of key population in the catchment area	2,800



KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,800
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	2,800
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	90,011
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	78,464
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	11,547
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	90,011
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	90,011
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,652
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	291
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	79,843
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	10,168

### Implementing Mechanism Details

<b>Mechanism ID: 14232</b>	<b>Mechanism Name: Yekokeb Berhan</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pact, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 185,901</b>	
<b>Applied Pipeline Amount: 1,814,099</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 2,000,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	185,901

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 14232</b>			
<b>Mechanism Name: Yekokeb Berhan</b>			
<b>Prime Partner Name: Pact, Inc.</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	125,901	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	10,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	50,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**



Approved



<b>Mechanism ID: 14267</b>	<b>Mechanism Name: Infrastructure development for health systems strengthening</b>
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 5,000,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 5,000,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 14267</b>			
<b>Mechanism Name: Infrastructure development for health systems strengthening</b>			
<b>Prime Partner Name: Regional Procurement Support Office/Frankfurt</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)



**Implementing Mechanism Details**

<b>Mechanism ID: 14309</b>	<b>Mechanism Name: Strengthening National Response to HIV/AIDS</b>
Funding Agency: USAID	Procurement Type: Umbrella Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 670,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 670,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	670,000

**Cross-Cutting Budget Attribution(s)**

Key Populations: FSW	87,100
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention

**Budget Code Information**

<b>Mechanism ID:</b>	14309		
<b>Mechanism Name:</b>	Strengthening National Response to HIV/AIDS		
<b>Prime Partner Name:</b>	World Health Organization		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	60,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	490,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	120,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14351</b>	<b>Mechanism Name: Capacity Building of Local Organizations</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: National Network of Positive Women Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 205,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 205,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	205,000

### Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	20,500
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

**Budget Code Information**

<b>Mechanism ID:</b> 14351			
<b>Mechanism Name:</b> Capacity Building of Local Organizations			
<b>Prime Partner Name:</b> National Network of Positive Women Ethiopia			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	70,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	135,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 16738</b>	<b>Mechanism Name: Improving Public Health Practices and Service Delivery in the Federal Democratic Republic of Ethiopia with a Focus on HIV, Sexually Transmitted Infections, and Tuberculosis</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ethiopian Public Health Association	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



<b>Total All Funding Sources: 1,154,393</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,154,393</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,154,393

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16738		
<b>Mechanism Name:</b>	Improving Public Health Practices and Service Delivery in the Federal Democratic Republic of Ethiopia with a Focus on HIV, Sexually Transmitted Infections, and Tuberculosis		
<b>Prime Partner Name:</b>	Ethiopian Public Health Association		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	96,320	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	1,058,073	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of	47



	PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	
HRH_PRE	By Graduates: Other	47
HRH_PRE	Sum of Graduates disaggreagtes	47

### Implementing Mechanism Details

<b>Mechanism ID: 16742</b>	<b>Mechanism Name: Comprehensive HIV Prevention, Care and Treatment for the National Defense Force of Ethiopia (NDFE)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Defense Forces of Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 2,151,178</b>	
<b>Applied Pipeline Amount: 175,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,326,178</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,151,178

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	76,872
Food and Nutrition: Policy, Tools, and Service Delivery	24,936
Gender: GBV	34,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	16742		
<b>Mechanism Name:</b>	Comprehensive HIV Prevention, Care and Treatment for the National Defense Force of Ethiopia (NDFE)		
<b>Prime Partner Name:</b>	National Defense Forces of Ethiopia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	191,812	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	115,087	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	17,145	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	38,160	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	107,635	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	OHSS	76,872	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	81,374	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	428,699	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	38,477	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,021,627	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	34,290	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,590
PMTCT_ART_DSD	New on ART	27
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	45
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,590
PMTCT_STAT_DSD	Number of new ANC and L&D clients	2,726
PMTCT_STAT_DSD	By: Known positives at entry	47
PMTCT_STAT_DSD	By: Number of new positives identified	28
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	75





PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	76,500
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	67,000
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	9,500
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	60,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	42,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	12,000
HTC_TST_TA	Sum of Aggregated Age/Sex <15	6,000
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	54,000
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	60,000
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	3,000
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	6,000
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	6,000
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	22,657
HTC_TST_TA	Service Delivery Point (Facility): VCT	15,000
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	2,543
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	1,800
HTC_TST_TA	Service Delivery Point (Facility): Index testing	3,000
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	186



TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	190
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	140
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	36
GEND_GBV_DSD	Number of people receiving post-GBV care	100
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	40
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	60
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	54
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	60
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	60
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	48
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The	0



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	5,732
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	141
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	3,480
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	115
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	1,996
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	576
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	4,012
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,204
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,605
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	1,720
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	55
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	13
PMTCT_EID_DSD	Sum of Infant Age disaggregates	68
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,369



TX_CURR_DSD	Aggregated Age/Sex: <15 Male	157
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,866
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	128
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,218
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	285
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	6,084
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,369
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	588
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	17
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	351
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	17
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	203
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	588
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	3,439
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,822
TX_PVLS_DSD	Numerator: Indication: Routine	3,439
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	3,821
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	85
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	2,088
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	69
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	1,197
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	94
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	2,320
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	77
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,331



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	417
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	490
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	268
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	129
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	315
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	148



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	67
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	67
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	67
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	11
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	11
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	11
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	33
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	33
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of	33



	laboratories that achieve acceptable successful passing criteria in this PT program	
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0

**Implementing Mechanism Details**

<b>Mechanism ID: 16749</b>	<b>Mechanism Name: Technical Assistance for the Transition of Comprehensive HIV/AIDS Programs and Medical Education to Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 12,226,721</b>	
<b>Applied Pipeline Amount: 2,475,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 14,701,721</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	12,226,721



**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	138,971
Food and Nutrition: Policy, Tools, and Service Delivery	45,555
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	16749		
<b>Mechanism Name:</b>	Technical Assistance for the Transition of Comprehensive HIV/AIDS Programs and Medical Education to Ethiopia		
<b>Prime Partner Name:</b>	Columbia University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	851,105	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	477,482	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>





Care	PDCS	167,131	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	46,812	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	40,969	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	138,971	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	109,810	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	21,320	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	93,737	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	25,314	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	77,333	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	9,495,584	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	681,153	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	70,077
PMTCT_ART_DSD	New on ART	457
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	955
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	70,077
PMTCT_STAT_DSD	Number of new ANC and L&D clients	73,850
PMTCT_STAT_DSD	By: Known positives at entry	995
PMTCT_STAT_DSD	By: Number of new positives identified	511
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,506
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	13,284
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	6,524
VMMC_CIRC_DSD	By Age: 15-19	816
VMMC_CIRC_DSD	By Age: 20-24	397
VMMC_CIRC_DSD	By Age: 25-29	255
VMMC_CIRC_DSD	By Age: 30-49	3,321
VMMC_CIRC_DSD	By Age: 50+	1,971
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	9,708
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	13,284
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	13,284
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the	3,178



	minimum components during the reporting period.	
PP_PREV_DSD	Total number of people in the target population	3,812
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	511,323
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	46,405
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	178,495
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	44,710
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	241,713
HTC_TST_TA	Sum of Aggregated Age/Sex <15	91,115
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	420,208
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	511,323
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	211
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	934
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	184
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,231
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	52,132
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	199,841
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	0
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	34,743
HTC_TST_TA	Service Delivery Point (Facility): VCT	108,614
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	76,890
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	39,103



HTC_TST_TA	Service Delivery Point (Facility): Index testing	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,424
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	3,516
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	275
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,640
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	208
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,301
GEND_GBV_DSD	Number of people receiving post-GBV care	218
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	94
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	129
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	121
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	453
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	453
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	31
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The	230



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	22
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	170
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	17,065
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	740
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	5,968
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	617
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	9,740
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,712
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,201
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	3
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	4
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	1
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,005
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	251
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,256
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	21



PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	12
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	18,985
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	791
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,678
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	653
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	10,882
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,444
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	17,560
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	19,004
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,424
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	239
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,054
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	207
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,901
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,401
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	9,859
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	12,327
TX_PVLS_DSD	Numerator: Indication: Routine	7,888
TX_PVLS_DSD	Numerator: Indication: Targeted	1,971
TX_PVLS_DSD	Denominator: Indication: Routine	9,860
TX_PVLS_DSD	Denominator: Indication: Targeted	2,467
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	431
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	3,433
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	363
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	5,632



TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	540
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	4,299
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	447
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	7,041
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,614
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,917
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	155
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	825
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	128
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,506
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	175
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	916
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	147



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,679
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	71
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	76
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23





TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	44
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	59
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	59
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	59
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	32
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	11
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	11
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT	1



	program	
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	59
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	21
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	21
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	7
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	1,032
HRH_PRE	By Graduates: Doctors	973
HRH_PRE	By Graduates: Other	59
HRH_PRE	Sum of Graduates disaggregated	1,032

### Implementing Mechanism Details

<b>Mechanism ID: 16750</b>	<b>Mechanism Name: Technical assistance and collaboration with country and regional programs</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 837,370</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 837,370</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	837,370

**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Policy, Tools, and Service Delivery	734,551
---	---------

**Budget Code Information**

<b>Mechanism ID:</b>	16750		
<b>Mechanism Name:</b>	Technical assistance and collaboration with country and regional programs		
<b>Prime Partner Name:</b>	World Health Organization		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	431,576	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	78,321	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	327,473	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16751</b>	<b>Mechanism Name: Strengthening Capacity for Laboratory Systems, Strategic Information, and Technical Leadership in Public Health for the National HIV/AIDS Response in Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ethiopian Public Health Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 2,473,180</b>	
<b>Applied Pipeline Amount: 500,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,973,180</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,473,180

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	<b>16751</b>
<b>Mechanism Name:</b>	<b>Strengthening Capacity for Laboratory Systems, Strategic Information, and Technical Leadership in Public Health for the National HIV/AIDS</b>
<b>Prime Partner Name:</b>	<b>Response in Ethiopia</b>



Ethiopian Public Health Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	208,946	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	490,281	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	335,366	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,438,587	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	1
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1



LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1

### Implementing Mechanism Details



<b>Mechanism ID: 16752</b>	<b>Mechanism Name: Strengthening Local Ownership for the Sustainable Provision of HIV/AIDS Services in the Regional Health Bureaus (Amhara)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Amhara Regional Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 7,878,649</b>	
<b>Applied Pipeline Amount: 461,673</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 8,340,322</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	7,878,649

### Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	162,081
Renovation	900,000
Motor Vehicles: Purchased	520,000
Key Populations: FSW	66,553
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs



Gender: GBV	33,100
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	16752		
<b>Mechanism Name:</b>	Strengthening Local Ownership for the Sustainable Provision of HIV/AIDS Services in the Regional Health Bureaus (Amhara)		
<b>Prime Partner Name:</b>	Amhara Regional Health Bureau		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,246,776	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	278,127	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	164,143	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	HLAB	222,308	0





Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	206,514	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	75,676	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	50,927	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	116,941	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	131,382	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	532,520	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,923,049	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	930,286	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	323,709



	their results)	
PMTCT_ART_DSD	New on ART	1,692
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,306
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,405
PMTCT_ART_TA	New on ART	10
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	81
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	323,709
PMTCT_STAT_DSD	Number of new ANC and L&D clients	348,785
PMTCT_STAT_DSD	By: Known positives at entry	2,625
PMTCT_STAT_DSD	By: Number of new positives identified	1,801
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,426
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,405
PMTCT_STAT_TA	Number of new ANC and L&D clients	3,512
PMTCT_STAT_TA	By: Known positives at entry	84
PMTCT_STAT_TA	By: Number of new positives identified	12
PMTCT_STAT_TA	Sum of Positives Status disaggregates	96
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): <15	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	32,763
PP_PREV_DSD	Total number of people in the target population	42,985
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,691
KP_PREV_DSD	Total estimated number of key population in the catchment area	31,950



KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,691
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	30,712
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	42
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	221
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	417
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	212
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,646
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	433
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,063
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,496
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	11
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	4
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	12
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0



HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	2
HTC_TST_DSD	Service Delivery Point (Facility): VCT	6
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	16
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,427,743
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	110,577
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	434,061
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	107,997
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	768,702
HTC_TST_TA	Sum of Aggregated Age/Sex <15	218,574
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	1,202,763
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	1,421,337
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	947
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,646
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	807
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	9,959
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	126,170
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	564,428
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	0
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	82,580



HTC_TST_TA	Service Delivery Point (Facility): VCT	261,800
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	370,968
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	94,526
HTC_TST_TA	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	0
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	112
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	12,570
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	13,652
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,001
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6,037
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	751



TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,781
GEND_GBVDSD	Number of people receiving post-GBV care	1,049
GEND_GBVDSD	Age/Sex: <10 Female	1
GEND_GBVDSD	Sum of Age/Sex Disaggregates	1
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	477
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	595
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	584
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	5
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	5
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	1,027



	during TB treatment during the reporting period	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,022
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	48
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	552
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	24
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	392
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	125,746
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	4,737
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	44,368
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	4,238
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	71,875
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	12,586
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	8,812
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	2,651
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	3,522



TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	2,657
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	481
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	19
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	162
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	23
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	277
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	49
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	34
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	10
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	13
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	11
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,505
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	876
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,381
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	71
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	33
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	24
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	6
PMTCT_EID_TA	Sum of Infant Age disaggregates	30
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	4





PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	135,752
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,035
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	47,244
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,515
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	78,647
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	9,550
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	125,891
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	135,441
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2
TX_CURR_TA	Aggregated Age/Sex: <15 Male	0
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1
TX_CURR_TA	Aggregated Age/Sex: <15 Female	0
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1
TX_CURR_TA	Sum of Aggregated Age/Sex <15	0
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	2
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	15,487
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,064
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,967
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	894
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	8,531
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	15,456
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	71,309



TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	89,119
TX_PVLS_DSD	Numerator: Indication: Routine	57,036
TX_PVLS_DSD	Numerator: Indication: Targeted	14,247
TX_PVLS_DSD	Denominator: Indication: Routine	71,307
TX_PVLS_DSD	Denominator: Indication: Targeted	17,813
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	2,734
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	25,071
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,463
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	41,037
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3,398
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	31,212
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	3,047
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	51,026
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1
TX_PVLS_TA	Numerator: Indication: Routine	1
TX_PVLS_TA	Numerator: Indication: Targeted	0
TX_PVLS_TA	Denominator: Indication: Routine	1
TX_PVLS_TA	Denominator: Indication: Targeted	0
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	0
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	1
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	0
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	0
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	5
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	39
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	5



TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	69
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	10,110
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	11,384
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	603
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,174
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	505
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,826
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	683
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,578
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	573
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total	6,567



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	20
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	1



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	341
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	341
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	341
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	28
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	24
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	24
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	5
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	5
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	5
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	5
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of	341



	laboratories that perform this testing	
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	24
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	24
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	18
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	3
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	2
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	2
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2

**Implementing Mechanism Details**

<b>Mechanism ID: 16779</b>	<b>Mechanism Name: Technical Assistance for System Development for Accreditation of Laboratories and Implementation of Improved Diagnostic Technologies in Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 85,503</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 85,503</b>	



Funding Source	Funding Amount
GHP-State	85,503

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	16779		
<b>Mechanism Name:</b>	Technical Assistance for System Development for Accreditation of Laboratories and Implementation of Improved Diagnostic Technologies		
<b>Prime Partner Name:</b>	in Ethiopia African Society for Laboratory Medicine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	85,503	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 16798</b>	<b>Mechanism Name: FHI 360 Ethiopia</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 31,736</b>	
--	--



<b>Applied Pipeline Amount: 268,264</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	31,736

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 16798</b>			
<b>Mechanism Name: FHI 360 Ethiopia</b>			
<b>Prime Partner Name: FHI 360</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	31,736	0

### Implementing Mechanism Indicator Information

<b>Indicator Number</b>	<b>Label</b>	<b>2017</b>
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,080
PP_PREV_TA	Total number of people in the target population	2,600
PP_PREV_TA	Aggregated Age/sex: 15+ Male	210
PP_PREV_TA	Aggregated Age/sex: 15+ Female	1,870
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,880





KP_PREV_TA	Total estimated number of key population in the catchment area	2,350
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,880
KP_PREV_TA	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	2,350
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	11,090
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,436
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,654
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	11,090
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	11,090
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	35
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	93
HTC_TST_TA	Service Delivery Point (Community): Mobile testing	7,480
HTC_TST_TA	Service Delivery Point (Community): Other	3,610

### Implementing Mechanism Details

<b>Mechanism ID: 16901</b>	<b>Mechanism Name: Strengthening local ownership for sustainable provision of HIV/AIDS services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: SNNPR	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: Yes	Managing Agency: HHS/CDC
<b>Total All Funding Sources: 4,862,338</b>	
<b>Applied Pipeline Amount: 110,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,972,338</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,862,338

**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Policy, Tools, and Service Delivery	75,219
Renovation	360,000
Motor Vehicles: Purchased	160,000
Key Populations: FSW	16,146
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	21,151
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	16901		
<b>Mechanism Name:</b>	Strengthening local ownership for sustainable provision of HIV/AIDS services		
<b>Prime Partner Name:</b>	SNNPR		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	578,607	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	191,812	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	90,011	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	152,426	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	200,099	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	OHSS	61,872	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	27,963	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	95,087	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	30,366	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	391,624	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,819,691	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	222,780	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	172,192
PMTCT_ART_DSD	New on ART	379
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,163
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	549
PMTCT_ART_TA	New on ART	2
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	2



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	172,192
PMTCT_STAT_DSD	Number of new ANC and L&D clients	182,153
PMTCT_STAT_DSD	By: Known positives at entry	1,236
PMTCT_STAT_DSD	By: Number of new positives identified	366
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,602
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	0
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	549
PMTCT_STAT_TA	Number of new ANC and L&D clients	557
PMTCT_STAT_TA	By: Known positives at entry	2
PMTCT_STAT_TA	By: Number of new positives identified	2
PMTCT_STAT_TA	Sum of Positives Status disaggregates	4
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,609
PP_PREV_DSD	Total number of people in the target population	1,925
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	600
KP_PREV_DSD	Total estimated number of key population in the catchment area	6,991
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	600
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence	0



	and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	6,991
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	741,139
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	73,856
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	209,400
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	70,954
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	386,929
HTC_TST_TA	Sum of Aggregated Age/Sex <15	144,810
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	596,329
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	741,139
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	249
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,182
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	239
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,444
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	65,646
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	251,586
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	0
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	43,733
HTC_TST_TA	Service Delivery Point (Facility): VCT	136,742
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0



HTC_TST_TA	Service Delivery Point (Facility): PMTCT	192,763
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	49,222
HTC_TST_TA	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	0
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	0
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,498
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	3,614
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	284
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,678
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	211
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with	1,325



	documented HIV status, during the reporting period)	
GEND_GBVDSD	Number of people receiving post-GBV care	344
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	146
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	198
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	172
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	226
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	226



TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	129
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	83
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	30,232
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,468
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	10,689
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,306
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	16,769
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	3,051
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,121
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	639
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	844
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	637
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,121



PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	284
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,405
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	18
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	12
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	38,716
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,911
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	13,747
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,746
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	21,310
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,657
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	35,057
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	38,714
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,176
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	391
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,671
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	352
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,760
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,174
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	19,911
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	24,869
TX_PVLS_DSD	Numerator: Indication: Routine	15,926



TX_PVLS_DSD	Numerator: Indication: Targeted	3,985
TX_PVLS_DSD	Denominator: Indication: Routine	19,908
TX_PVLS_DSD	Denominator: Indication: Targeted	4,979
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	993
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	7,063
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	909
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	10,946
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,239
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	8,832
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,135
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	13,681
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,394
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,910
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	207
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,099
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	179
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,025
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	234



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,231
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	195
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,250
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	85
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	85
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	85
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	32
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	24
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	24
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this	1



	testing	
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	85
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	22
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	22
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	18
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	3
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1

### Implementing Mechanism Details

<b>Mechanism ID: 16912</b>	<b>Mechanism Name: Health Finance and Governance</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,800,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,800,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,800,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16912		
<b>Mechanism Name:</b>	Health Finance and Governance		
<b>Prime Partner Name:</b>	Abt Associates		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	1,000,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	2,800,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

Approved



<b>Mechanism ID: 16930</b>	<b>Mechanism Name: Household Economic Strengthening</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 500,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 500,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	500,000

**Cross-Cutting Budget Attribution(s)**

Economic Strengthening	500,000
------------------------	---------

**Budget Code Information**

<b>Mechanism ID:</b>	16930		
<b>Mechanism Name:</b>	Household Economic Strengthening		
<b>Prime Partner Name:</b>	FHI 360		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	500,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**



<b>Mechanism ID: 17000</b>	<b>Mechanism Name: Strengthening Local Ownership for the Sustainable Provision of Comprehensive HIV/AIDS Services by the Health Bureau of Tigray Regional State of the Federal Democratic Republic of Ethiopia under the President's Emergency Plan for AIDS Relief (PEPFAR)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tigray Regional Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 4,524,745</b>	
<b>Applied Pipeline Amount: 150,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,674,745</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,524,745

**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Policy, Tools, and Service Delivery	87,274
Renovation	289,864
Motor Vehicles: Purchased	200,000
Key Populations: FSW	39,331
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs





Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	43,211
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b> <b>Mechanism Name:</b> <b>Prime Partner Name:</b>	<b>17000</b> <b>Strengthening Local Ownership for the Sustainable Provision of Comprehensive HIV/AIDS Services by the Health Bureau of Tigray Regional State of the Federal Democratic Republic of Ethiopia under the President's Emergency Plan for AIDS Relief (PEPFAR)</b> <b>Tigray Regional Health Bureau</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	671,341	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	191,812	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	PDCS	108,182	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	80,087	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	77,867	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	67,056	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	15,309	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	65,496	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	73,328	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	211,137	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,656,231	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	306,899	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	147,861
PMTCT_ART_DSD	New on ART	665
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	980
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	147,861
PMTCT_STAT_DSD	Number of new ANC and L&D clients	158,157
PMTCT_STAT_DSD	By: Known positives at entry	1,221
PMTCT_STAT_DSD	By: Number of new positives identified	659
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,880
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	10,057
PP_PREV_DSD	Total number of people in the target population	613
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,940
KP_PREV_DSD	Total estimated number of key population in the catchment area	5,151
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,940
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	5,151
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	472,472



HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	40,504
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	118,502
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	39,246
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	274,220
HTC_TST_TA	Sum of Aggregated Age/Sex <15	79,750
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	392,722
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	472,472
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	332
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,716
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	337
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	4,232
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	36,936
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	141,584
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	0
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	24,611
HTC_TST_TA	Service Delivery Point (Facility): VCT	76,972
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	164,670
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	27,700
HTC_TST_TA	Service Delivery Point (Facility): Index testing	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	7,830
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	8,106



TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	628
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,754
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	473
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,975
GEND_GBV_DSD	Number of people receiving post-GBV care	527
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	232
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	294
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	281
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	477
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	477
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	277
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	8

	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	177
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	40,717
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,542
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	13,345
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,426
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	24,404
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	4,063
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,852
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	854
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,135
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	863
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	1
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,440
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	364
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,804
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	23
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	13



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	42,713
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,552
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	13,863
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,426
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	25,872
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,978
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	39,735
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	42,713
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,448
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	389
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,898
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	389
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,771
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,447
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	22,128
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	27,645
TX_PVLS_DSD	Numerator: Indication: Routine	17,709
TX_PVLS_DSD	Numerator: Indication: Targeted	4,419
TX_PVLS_DSD	Denominator: Indication: Routine	22,113
TX_PVLS_DSD	Denominator: Indication: Targeted	5,530
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	826



TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	7,143
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	762
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	13,397
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,027
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	8,934
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	947
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	16,737
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,737
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,076
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	159
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	875
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	131
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,572
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	177
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	982





	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	151
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,770
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	167
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	167
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	167
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	19
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	13
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	13
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1



LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	167
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	63
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	63
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	7
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	3
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1

### Implementing Mechanism Details

<b>Mechanism ID: 17271</b>	<b>Mechanism Name: Capacity Building of Local Organizations</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Ethiopian Society of Sociologists, Social Workers and Anthropologists	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,300,000</b>	
---	--



<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,300,000

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,000,000
----------------------------	-----------

### Budget Code Information

<b>Mechanism ID:</b>	17271		
<b>Mechanism Name:</b>	Capacity Building of Local Organizations		
<b>Prime Partner Name:</b>	Ethiopian Society of Sociologists, Social Workers and Anthropologists		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	1,300,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	2,000
HRH_PRE	By Graduates: Social service workers	2,000
HRH_PRE	Sum of Graduates disaggreagtes	2,000

### Implementing Mechanism Details

<b>Mechanism ID: 17635</b>	<b>Mechanism Name: Challenge TB</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,000,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,000,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,000,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	501,029
Gender: Gender Equality	883,453
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation

**Budget Code Information**

<b>Mechanism ID:</b>	17635		
<b>Mechanism Name:</b>	Challenge TB		
<b>Prime Partner Name:</b>	KNCV Tuberculosis Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	2,000,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)



### Implementing Mechanism Details

<b>Mechanism ID: 17641</b>	<b>Mechanism Name: Advancing Partners and Communities (APC)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 300,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17641		
<b>Mechanism Name:</b>	Advancing Partners and Communities (APC)		
<b>Prime Partner Name:</b>	John Snow Inc (JSI)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	300,000	0

### Implementing Mechanism Indicator Information



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17746</b>	<b>Mechanism Name: Peace Corps/Ethiopia Volunteer Trainings and Small Grants</b>
Funding Agency: PC	Procurement Type: Cooperative Agreement
Prime Partner Name: Peace Corps Volunteers	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 70,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 70,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17746</b>			
<b>Mechanism Name: Peace Corps/Ethiopia Volunteer Trainings and Small Grants</b>			
<b>Prime Partner Name: Peace Corps Volunteers</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,115
PP_PREV_DSD	Total number of people in the target population	90,057
PP_PREV_DSD	Aggregated Age/sex: <15 Male	199
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	650
PP_PREV_DSD	Aggregated Age/sex: <15 Female	234
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,030
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	420
OVC_SERV_DSD	Age/Sex: 18+ Male	6
OVC_SERV_DSD	Age/Sex: 18+ Female	24
OVC_SERV_DSD	Sum of Age/Sex disaggregates	30
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	195
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	195

### Implementing Mechanism Details

<b>Mechanism ID: 17824</b>	<b>Mechanism Name: Private Health Sector Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,988,294</b>	
---	--



<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,988,294</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,988,294

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	150,000
Gender: Gender Equality	150,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Motor Vehicles: Purchased	179,311

**Budget Code Information**

<b>Mechanism ID:</b>	17824		
<b>Mechanism Name:</b>	Private Health Sector Project		
<b>Prime Partner Name:</b>	Abt Associates		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	349,405	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	454,226	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>





Care	PDCS	69,881	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	139,762	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	613,294	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	595,238	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	285,714	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	838,571	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,362,679	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	279,524	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	30,024
PMTCT_ART_TA	New on ART	243



PMTCT_ART_TA	Already on ART at beginning of current pregnancy	216
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	30,024
PMTCT_STAT_TA	Number of new ANC and L&D clients	30,939
PMTCT_STAT_TA	By: Known positives at entry	212
PMTCT_STAT_TA	By: Number of new positives identified	242
PMTCT_STAT_TA	Sum of Positives Status disaggregates	454
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	264,249
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,708
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	101,508
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,497
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	155,536
HTC_TST_TA	Sum of Aggregated Age/Sex <15	7,205
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	257,044
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	264,249
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	68
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,709
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	62
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	5,230
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	134,012



HTC_TST_TA	Service Delivery Point (Facility): VCT	99,818
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	24,403
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	2,534
HTC_TST_TA	Service Delivery Point (Facility): Index testing	1,297
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	0
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,547
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	2,767
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	84
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,276
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	67
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,129
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	420
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	420
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10



TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	213
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	190
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	8,329
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	360
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	2,877
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	326
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	4,766
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	228
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	44
PMTCT_EID_TA	Sum of Infant Age disaggregates	272
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	7,934
TX_CURR_TA	Aggregated Age/Sex: <15 Male	344
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	2,740
TX_CURR_TA	Aggregated Age/Sex: <15 Female	312
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	4,538



TX_CURR_TA	Sum of Aggregated Age/Sex <15	656
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	7,278
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	7,934
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,177
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	73
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	1,586
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	60
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,458
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	3,177
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	4,294
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	4,766
TX_PVLS_TA	Numerator: Indication: Routine	4,294
TX_PVLS_TA	Denominator: Indication: Routine	4,766
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	190
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	1,480
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	171
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	2,413
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	209
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	1,645
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	187
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	2,727
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	779
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	964



TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	198
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	109
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	412
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	84
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	236
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	137
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	511
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	259



LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	259
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	259
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	180
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	180
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	180

**Implementing Mechanism Details**

Mechanism ID: 17825	TBD: Yes
REDACTED	

**Implementing Mechanism Details**

Mechanism ID: 17843	TBD: Yes
REDACTED	

**Implementing Mechanism Details**

Mechanism ID: 17856	TBD: Yes
REDACTED	

**Implementing Mechanism Details**

Mechanism ID: 17908	TBD: Yes
REDACTED	

**Implementing Mechanism Details**



<b>Mechanism ID: 18233</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18241</b>	<b>Mechanism Name: Infrastructure Program - Engineering</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Tera Tech EM, INC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 4,000,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,000,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18241		
<b>Mechanism Name:</b>	Infrastructure Program - Engineering		
<b>Prime Partner Name:</b>	Tera Tech EM, INC		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0





### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

Mechanism ID: 18242	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 18265	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 18337	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 18338	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 18339	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 18340	TBD: Yes
---------------------	----------



**REDACTED**

**Implementing Mechanism Details**

<b>Mechanism ID: 18341</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18375</b>	<b>Mechanism Name: Global Health Supply Chain Program</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 16,086,433</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 16,086,433</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	16,086,433

**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Commodities	3,202,094
Human Resources for Health	450,000

**Budget Code Information**

<b>Mechanism ID: 18375</b>	
----------------------------	--



<b>Mechanism Name:</b> Global Health Supply Chain Program			
<b>Prime Partner Name:</b> Global Health Supply Chain Program			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	3,202,094	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	2,450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	746,276	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	8,948,063	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18463</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**



<b>Mechanism ID: 18464</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Agency Information - Costs of Doing Business  
U.S. Agency for International Development**

<b>Agency Cost of Doing Business</b>	<b>GAP</b>	<b>GHP-State</b>	<b>GHP-USAID</b>	<b>Applied Pipeline</b>	<b>Total</b>	<b>Total All Cost of Doing Business Categories and Applied Pipeline Amount</b>
Computers/IT Services		263,500		0	263,500	263,500
ICASS		1,268,995		0	1,268,995	1,268,995
Institutional Contractors				0	0	0
Management Meetings/Professional Development		247,250		0	247,250	247,250
Non-ICASS Administrative Costs		259,300		0	259,300	259,300
Staff Program Travel		314,722		0	314,722	314,722
USG Staff Salaries and Benefits - Internationally Recruited		614,830		1,190,305	614,830	1,805,135
USG Staff Salaries and Benefits -		0		1,207,925	0	1,207,925



Locally Recruited						
<b>Total</b>	<b>0</b>	<b>2,968,597</b>	<b>0</b>	<b>2,398,230</b>	<b>2,968,597</b>	<b>5,366,827</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
ICASS		29,499		0	29,499	29,499
Institutional Contractors				0	0	0
Management Meetings/Professional Development		22,546		0	22,546	22,546
Non-ICASS Administrative Costs		42,965		0	42,965	42,965
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		31,940		0	31,940	31,940
USG Staff Salaries and Benefits - Locally Recruited		35,820		0	35,820	35,820
<b>Total</b>	<b>0</b>	<b>162,770</b>	<b>0</b>	<b>0</b>	<b>162,770</b>	<b>162,770</b>



### U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		1,256,200		250,000	1,256,200	1,506,200
Computers/IT Services		474,100		0	474,100	474,100
ICASS		1,703,600		0	1,703,600	1,703,600
Institutional Contractors				0	0	0
Management Meetings/Professional Development		419,000		0	419,000	419,000
Non-ICASS Administrative Costs		504,300		0	504,300	504,300
Staff Program Travel	0	583,700		0	583,700	583,700
USG Renovation		680,000		0	680,000	680,000
USG Staff Salaries and Benefits - Internationally	1,703,100	0		1,375,000	1,703,100	3,078,100



Recruited						
USG Staff Salaries and Benefits - Locally Recruited	1,084,400	1,338,700		375,000	2,423,100	2,798,100
<b>Total</b>	<b>2,787,500</b>	<b>6,959,600</b>	<b>0</b>	<b>2,000,000</b>	<b>9,747,100</b>	<b>11,747,100</b>

**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
ICASS		60,000		0	60,000	60,000
Institutional Contractors				0	0	0
Management Meetings/Professional Development		20,000		0	20,000	20,000
Non-ICASS Administrative Costs		25,000		0	25,000	25,000
Non-ICASS Motor Vehicles		10,000		0	10,000	10,000
Staff Program Travel		40,000		0	40,000	40,000
USG Staff Salaries and		52,164		174,218	52,164	226,382



Benefits - Internationally Recruited						
USG Staff Salaries and Benefits - Locally Recruited		189,218		0	189,218	189,218
<b>Total</b>	<b>0</b>	<b>396,382</b>	<b>0</b>	<b>174,218</b>	<b>396,382</b>	<b>570,600</b>

**U.S. Peace Corps**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Institutional Contractors				0	0	0
Non-ICASS Administrative Costs		0		123,494	0	123,494
Peace Corps Volunteer Costs				151,521	0	151,521
Staff Program Travel		0		107,007	0	107,007
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0



Approved



USG Staff Salaries and Benefits - Locally Recruited		0		158,321	0	158,321
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>540,343</b>	<b>0</b>	<b>540,343</b>